Biotech Industry Financials, Performance and Ratios
-
Industry Score
36.6 /100
Rank 80 out of 131 Industries -
Advance/Decline
162/122
-
No. of Companies284
-
Avg. Market Cap2,814
-
Price to Earning Ratio6.31
-
Price to Earning Growth Ratio0.32
-
Price to Book Ratio14.79
-
Return on Equity13.01
-
Return on Capital Employed-
-
Return on Assets4.85
-
Dividend yield 1 year %0.29 %
-
Net Profit Growth Annual YoY %57.58 %
-
Net Profit Growth Qtr YoY %96.50 %
-
Net Profit Growth Qtr QoQ %88.17 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,660.5
|
23.4
|
L
 -3.2%
H
23.3
24.4
|
L
 2.4%
H
22.6
24.4
|
L
 1.8%
H
22.1
25.7
|
L
 -4.5%
H
22.1
27.7
|
L
 169.0%
H
8.0
27.7
|
L
 151.6%
H
7.9
27.7
|
L
 -21.1%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
1,675.8
|
4.8
|
L
 -0.6%
H
4.8
4.9
|
L
 6.9%
H
4.4
4.9
|
L
 8.6%
H
4.0
4.9
|
L
 -23.6%
H
4.0
6.5
|
L
 138.6%
H
1.6
9.8
|
L
 167.8%
H
1.0
9.8
|
L
 -58.3%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
2,885.5
|
23.0
|
L
 0.0%
H
22.6
23.9
|
L
 4.3%
H
22.1
23.9
|
L
 4.8%
H
20
23.9
|
L
 -6.3%
H
18.5
24.9
|
L
 199.7%
H
7.1
26.4
|
L
 31.2%
H
6.5
26.4
|
L
 -30.7%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
181.7
|
3.9
|
L
 -3.8%
H
3.8
4.1
|
L
 12.2%
H
3.3
4.1
|
L
 -1.5%
H
3.2
4.1
|
L
 32.8%
H
2.6
4.5
|
L
 125.2%
H
1.4
4.5
|
L
 -52.4%
H
1.2
8.7
|
L
 -79.5%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,158.1
|
3.8
|
L
 1.6%
H
3.8
3.9
|
L
 15.8%
H
3.4
3.9
|
L
 9.5%
H
3.2
3.9
|
L
 -11.0%
H
2.7
4.9
|
L
 56.6%
H
1.9
6.5
|
L
 -48.2%
H
1.9
8.1
|
L
 -86.5%
H
1.9
36.1
|
L
H
1.9
71.9
|
| Arcellx Inc |
|
6,730.4
|
115.1
|
L
 0.2%
H
114.9
115.1
|
L
 0.3%
H
114.8
115.1
|
L
 0.6%
H
114.3
115.1
|
L
 64.7%
H
63.1
115.1
|
L
 90.9%
H
47.9
115.1
|
L
 271.1%
H
30.7
115.1
|
L
H
6.0
115.1
|
L
H
6.0
115.1
|
| Adma Biologics Inc |
|
2,531.6
|
10.6
|
L
 1.3%
H
10.5
10.7
|
L
 14.8%
H
9.3
10.8
|
L
 -29.8%
H
7.2
16.4
|
L
 -41.9%
H
7.2
18.3
|
L
 -49.2%
H
7.2
25.7
|
L
 234.3%
H
3.1
25.7
|
L
 518.0%
H
1.0
25.7
|
L
 42.9%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,263.5
|
14.7
|
L
 1.2%
H
14.4
14.9
|
L
 7.2%
H
12.4
15.6
|
L
 11.6%
H
12.0
15.6
|
L
 -18.5%
H
12
19.8
|
L
 88.0%
H
6.8
20.8
|
L
 85.8%
H
2.3
20.8
|
L
 -65.5%
H
2.3
45.0
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.4
|
0.4
|
L
 2.4%
H
0.4
0.4
|
L
 -17.3%
H
0.4
0.5
|
L
 -76.4%
H
0.4
1.8
|
L
 -92.6%
H
0.4
14.7
|
L
 -100.0%
H
0.4
2594.5
|
L
 -100.0%
H
0.4
10000000000
|
L
 -100.0%
H
0.4
10000000000
|
L
H
0.4
10000000000
|
| Agenus Inc |
|
183.9
|
4.8
|
L
 1.5%
H
4.6
5.1
|
L
 18.0%
H
3.9
5.1
|
L
 54.5%
H
2.9
5.1
|
L
 2.4%
H
2.7
5.1
|
L
 169.1%
H
1.6
7.3
|
L
 -83.2%
H
1.4
196
|
L
 -90.9%
H
1.4
196
|
L
 -94.4%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
259.2
|
64.0
|
L
 1.2%
H
60.8
67.7
|
L
 25.0%
H
50.4
75
|
L
 60.5%
H
40.7
75
|
L
 93.0%
H
30.9
75
|
L
 321.7%
H
13.9
75
|
L
 1606.9%
H
2.7
75
|
L
 -66.1%
H
2.7
217
|
L
 -73.8%
H
2.7
300
|
| Avalon GloboCare Corp |
|
3.1
|
0.4
|
L
 -9.8%
H
0.4
0.4
|
L
 -31.5%
H
0.4
0.6
|
L
 -46.4%
H
0.4
0.7
|
L
 -67.0%
H
0.4
1.6
|
L
 -90.2%
H
0.4
5.2
|
L
 -81.8%
H
0.2
11.7
|
L
 -96.3%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
110.7
|
1.8
|
L
 2.8%
H
1.8
1.9
|
L
 21.1%
H
1.5
1.9
|
L
 -55.3%
H
1.1
4.5
|
L
 -56.6%
H
1.1
5.9
|
L
 -13.2%
H
1.1
6.2
|
L
 -82.4%
H
1.1
12.0
|
L
 -84.3%
H
1.1
16.0
|
L
 -66.2%
H
1.1
16.7
|
| Alector Inc |
|
281.4
|
2.6
|
L
 5.8%
H
2.5
2.6
|
L
 3.2%
H
2.3
2.6
|
L
 15.9%
H
2.0
2.6
|
L
 37.8%
H
1.7
2.7
|
L
 160.2%
H
0.9
3.4
|
L
 -60.5%
H
0.9
9.1
|
L
 -85.5%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
502.2
|
2.1
|
L
 -9.7%
H
1.9
2.1
|
L
 -21.4%
H
1.9
4.5
|
L
 -14.2%
H
1.9
4.5
|
L
 21.2%
H
1.5
4.5
|
L
 44.1%
H
0.9
4.5
|
L
 -58.7%
H
0.9
6.9
|
L
 -93.6%
H
0.9
35.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
439.8
|
3.4
|
L
 2.7%
H
3.3
3.4
|
L
H
3.2
3.5
|
L
 -3.4%
H
2.9
3.7
|
L
 -19.1%
H
2.9
6.4
|
L
 -27%
H
2.9
7.7
|
L
 -29.3%
H
2.1
14.8
|
L
 -73.9%
H
2.1
23.5
|
L
 -99.5%
H
1.5
1050
|
| Alvotech |
|
1,139.0
|
3.7
|
L
 3.4%
H
3.6
3.7
|
L
 7.7%
H
3.4
3.8
|
L
 5.2%
H
3.0
3.9
|
L
 -27%
H
3.0
5.6
|
L
 -57.2%
H
3.0
11.9
|
L
 -65.8%
H
3.0
18
|
L
H
3.0
18
|
L
H
3.0
18
|
| Kalaris Therapeutics Inc |
|
136.7
|
6.0
|
L
 2.4%
H
5.4
6.0
|
L
 -7.7%
H
5.4
7.1
|
L
 -31.3%
H
5.2
9.3
|
L
 -35.5%
H
5.2
11.2
|
L
 -13.4%
H
2.1
11.9
|
L
 53.6%
H
0.4
12.9
|
L
 -74.7%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Amgen |
|
187,056.5
|
347
|
L
 -1.1%
H
344.2
352.6
|
L
 2.1%
H
342.4
359.4
|
L
 -5.3%
H
335.1
370.9
|
L
 5.5%
H
321.7
391.3
|
L
 18.1%
H
261.4
391.3
|
L
 38.8%
H
211.7
391.3
|
L
 39.0%
H
198.6
391.3
|
L
 116.7%
H
133.6
391.3
|
| AnaptysBio Inc |
|
1,982.8
|
69.0
|
L
 -1.8%
H
68.6
70.6
|
L
 11.0%
H
62.7
73.3
|
L
 6.4%
H
54.2
73.3
|
L
 37.2%
H
44.3
73.3
|
L
 286.2%
H
17.1
73.3
|
L
 220.3%
H
12.2
73.3
|
L
 224.3%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,747.0
|
76.8
|
L
 -1.9%
H
75.9
78.5
|
L
 -3.4%
H
75.9
82.1
|
L
 8.9%
H
70.4
82.1
|
L
 -9.7%
H
70.2
87.1
|
L
 11.7%
H
56.7
99.5
|
L
 99.9%
H
37.0
99.5
|
L
 127.9%
H
22.3
99.5
|
L
 78.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
95.9
|
2.9
|
L
 -0.7%
H
2.8
2.9
|
L
 6.3%
H
2.6
2.9
|
L
 1.1%
H
2.4
2.9
|
L
 -13.6%
H
2.4
3.4
|
L
 7.9%
H
2.4
5.5
|
L
 -52.1%
H
2.1
6.5
|
L
 -37.8%
H
2.1
6.5
|
L
 2.1%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
110.4
|
3.1
|
L
 3.0%
H
2.9
3.1
|
L
 -7.0%
H
2.9
3.5
|
L
 -37.9%
H
2.9
5.2
|
L
 134.4%
H
1
6.9
|
L
 134.4%
H
1
6.9
|
L
 -65.0%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
3.7
|
0.7
|
L
 12.1%
H
0.6
0.8
|
L
 4.8%
H
0.5
0.8
|
L
 -14.5%
H
0.5
0.9
|
L
 -59.9%
H
0.5
1.7
|
L
 -95.3%
H
0.5
14.2
|
L
 -100.0%
H
0.5
27900
|
L
 -100.0%
H
0.5
121500
|
L
 -100.0%
H
0.5
2167200
|
| Aptevo Therapeutics Inc |
|
6.2
|
5.3
|
L
 4.6%
H
5.0
5.4
|
L
 26.1%
H
4
5.4
|
L
 19%
H
3.8
5.4
|
L
 -41.6%
H
3.8
10.7
|
L
 -98.6%
H
3.8
486
|
L
 -100.0%
H
3.8
1224907.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
5.4
|
1.1
|
L
 2.9%
H
1
1.2
|
L
 18.0%
H
0.9
1.2
|
L
 11.7%
H
0.9
1.2
|
L
 -0.9%
H
0.8
1.2
|
L
 61.5%
H
0.6
3.0
|
L
 -90.9%
H
0.5
11.9
|
L
 -99.2%
H
0.5
130.6
|
L
H
0.5
610
|
| Arvinas Inc |
|
697.8
|
10.9
|
L
 -0.8%
H
10.6
11.1
|
L
 -4.1%
H
10.6
12.1
|
L
 -10.4%
H
10.0
12.5
|
L
 -10.6%
H
10.0
14.5
|
L
 47.4%
H
5.9
14.5
|
L
 -59.4%
H
5.9
53.1
|
L
 -82.7%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
9,728.0
|
69.5
|
L
 4.2%
H
66.6
69.7
|
L
 13.6%
H
63.2
69.7
|
L
 26.2%
H
54.9
69.7
|
L
 5.4%
H
54.0
76.1
|
L
 463.0%
H
10.9
76.8
|
L
 128.1%
H
9.6
76.8
|
L
 3.4%
H
9.6
93.7
|
L
 1024.1%
H
1.2
93.7
|
| LeonaBio Inc |
|
86.8
|
9.2
|
L
 1.9%
H
8.9
9.7
|
L
 -20.9%
H
8.9
11.9
|
L
 20.6%
H
6.9
14.2
|
L
 40.4%
H
4.2
14.2
|
L
 255.4%
H
2.2
14.2
|
L
 -64.0%
H
2.2
43.0
|
L
 -94.7%
H
2.2
236.4
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,123.5
|
16.0
|
L
 -0.6%
H
15.8
16.1
|
L
 1.1%
H
15.6
16.5
|
L
 14.5%
H
13.8
16.5
|
L
 4.9%
H
13.5
16.5
|
L
 106.6%
H
7.3
16.5
|
L
 42.3%
H
4.7
16.5
|
L
 26.8%
H
4.1
34.0
|
L
 441.4%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
451.0
|
7.0
|
L
 -0.9%
H
7
7.2
|
L
 6.0%
H
6.6
7.2
|
L
 18.4%
H
5.9
7.2
|
L
 33.7%
H
4.7
7.2
|
L
 29.0%
H
4.3
7.5
|
L
 -19.2%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
549.0
|
29.2
|
L
 -2.4%
H
28.9
30.4
|
L
 0.7%
H
28.9
31.5
|
L
 -12.2%
H
28.2
34.5
|
L
 48.7%
H
16.8
36.0
|
L
 63.6%
H
14.4
36.0
|
L
 158.3%
H
1.4
61.1
|
L
 -78.3%
H
1.4
144.1
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
951.8
|
19.3
|
L
 -0.7%
H
19.1
20.1
|
L
 18.0%
H
16.3
20.1
|
L
 38.7%
H
12.9
20.1
|
L
 31.7%
H
12.9
20.1
|
L
 -79.7%
H
6.6
100.1
|
L
 -96.7%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
297.5
|
3.2
|
L
 2.9%
H
3.1
3.2
|
L
 4.2%
H
2.9
3.3
|
L
 -31.0%
H
2.6
4.8
|
L
 -33.4%
H
2.6
5.4
|
L
 -63.6%
H
2.6
14.0
|
L
 -59.3%
H
2.6
14.4
|
L
 -75.1%
H
2.6
31.5
|
L
 -43.4%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
9,411.2
|
184.0
|
L
 -0.1%
H
179.6
185.1
|
L
 9.0%
H
167.1
185.1
|
L
 17.9%
H
152.3
185.1
|
L
 3.9%
H
152.3
191.5
|
L
 77.7%
H
96.1
191.5
|
L
 168.6%
H
55.0
191.5
|
L
 243.6%
H
19.4
191.5
|
L
 1765.9%
H
1.9
191.5
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.1
|
L
 3.6%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 5.6%
H
1.0
1.2
|
L
 35.7%
H
0.7
1.4
|
L
 -33.7%
H
0.5
2.6
|
L
 -20.8%
H
0.5
2.8
|
L
 -91.3%
H
0.5
13.3
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
5.2
|
4.6
|
L
 -1.5%
H
4.6
4.8
|
L
 20%
H
3.6
4.8
|
L
 -50.2%
H
3.3
9.5
|
L
 -57.5%
H
3.3
11.6
|
L
 -89.8%
H
3.3
63.2
|
L
 -97.1%
H
3.3
219.8
|
L
 -99.7%
H
3.3
2192
|
L
 -100.0%
H
3.3
17759.8
|
| Autolus Therapeutics PLC (ADR) |
|
388.6
|
1.5
|
L
 -1.4%
H
1.5
1.5
|
L
 7.4%
H
1.4
1.6
|
L
 1.4%
H
1.2
1.6
|
L
 2.8%
H
1.2
1.9
|
L
 9.0%
H
1.2
2.7
|
L
 -18.9%
H
1.1
7.5
|
L
 -73.9%
H
1.1
8.2
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
14,958.5
|
77.2
|
L
 -1.0%
H
76.2
78.9
|
L
 7.3%
H
73.1
79.5
|
L
 11.2%
H
67.6
79.5
|
L
 -1.0%
H
62.8
84.9
|
L
 121.4%
H
31.8
84.9
|
L
 423.5%
H
12.8
84.9
|
L
 38.4%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
7.5
|
4.5
|
L
 5.6%
H
4.3
4.5
|
L
 -3.2%
H
4.2
5.2
|
L
 -45.3%
H
3.9
10.3
|
L
 -73.4%
H
3.9
19.3
|
L
 -71.4%
H
3.9
71.5
|
L
 -97.5%
H
3.9
203.4
|
L
 -99.8%
H
3.9
2873
|
L
H
3.9
3831.5
|
| BioCardia Inc |
|
13.0
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
H
1.1
1.3
|
L
 -5.6%
H
1.1
1.4
|
L
 -16.2%
H
1.1
1.4
|
L
 -39.9%
H
1
3.2
|
L
 -96.0%
H
1
43.8
|
L
 -98.1%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,372.6
|
9.5
|
L
 -2.2%
H
9.4
9.8
|
L
 -1.4%
H
9.3
10.0
|
L
 15.1%
H
8.2
10.3
|
L
 39.5%
H
6.2
10.3
|
L
 34.4%
H
6
11.3
|
L
 17.2%
H
4.0
11.3
|
L
 -7.2%
H
4.0
20.0
|
L
 218.5%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
33.1
|
4.6
|
L
 0.4%
H
4.5
4.6
|
L
 2.9%
H
4.2
4.6
|
L
 8.1%
H
3.7
4.6
|
L
 -6.2%
H
3.6
5.2
|
L
 -99.0%
H
3.6
982
|
L
 -100.0%
H
3.6
11395.5
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
83250
|
| Black Diamond Therapeutics Inc |
|
158.1
|
2.8
|
L
 3.8%
H
2.7
2.8
|
L
 12.7%
H
2.4
2.8
|
L
 30.2%
H
2
2.8
|
L
 -1.1%
H
1.9
2.8
|
L
 97.1%
H
1.3
4.9
|
L
 85.2%
H
1.2
7.7
|
L
 -88.9%
H
1.2
29.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,082.2
|
30.3
|
L
 -0.1%
H
29.9
31.4
|
L
 23.6%
H
24.7
31.5
|
L
 20.3%
H
21.6
31.5
|
L
 -14.5%
H
21.6
35.5
|
L
 78%
H
15.4
36.4
|
L
 -3.2%
H
13.5
49.5
|
L
 -60.4%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
26,293.3
|
179.2
|
L
 0.1%
H
177.7
180.1
|
L
 2.0%
H
171.2
181.8
|
L
 -1.3%
H
168.6
192.3
|
L
 5.8%
H
160.4
202.4
|
L
 50.2%
H
114.7
202.4
|
L
 -37.8%
H
110.0
319.8
|
L
 -32.6%
H
110.0
468.6
|
L
 -28.1%
H
110.0
468.6
|
| BioVie Inc |
|
10.6
|
1.4
|
L
 -3.4%
H
1.4
1.5
|
L
 -2.1%
H
1.4
1.5
|
L
H
1.2
1.5
|
L
 16.5%
H
1.1
1.5
|
L
 -83.7%
H
1.1
13.2
|
L
 -99.8%
H
1.1
869
|
L
 -99.9%
H
1.1
2386
|
L
 -99.8%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,706.6
|
55.7
|
L
 0.4%
H
55.0
56.1
|
L
 -1.0%
H
53.9
57.8
|
L
 -4.9%
H
53.4
58.8
|
L
 -0.7%
H
53.4
66.3
|
L
 -6.7%
H
50.8
66.3
|
L
 -43.8%
H
50.8
100.4
|
L
 -28.8%
H
50.8
117.8
|
L
 -37.3%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
13.8
|
1.2
|
L
 2.5%
H
1.2
1.3
|
L
 6.0%
H
1.1
1.3
|
L
 11.7%
H
1.1
1.5
|
L
 -20%
H
1.1
1.8
|
L
 -74.3%
H
1.1
5.5
|
L
 -88.6%
H
0.1
11.6
|
L
 -98.1%
H
0.1
91.2
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
475.5
|
13.9
|
L
 4.8%
H
12.3
14.0
|
L
 27.2%
H
10.6
14.0
|
L
 18.1%
H
10.0
14.0
|
L
 14.4%
H
9.9
14.0
|
L
 4.6%
H
9.9
17.2
|
L
 282.4%
H
1.9
17.2
|
L
 -84.3%
H
1.9
99.6
|
L
 -96.8%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
10.2
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 -5.3%
H
1.2
1.4
|
L
 -14.9%
H
1.1
1.6
|
L
 -27.6%
H
1.1
1.7
|
L
 -23.6%
H
1.1
3.4
|
L
 -99.7%
H
1.1
390
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
29.2
|
1.1
|
L
 1.9%
H
1.1
1.1
|
L
 -0.9%
H
1.0
1.2
|
L
 -27.5%
H
1.0
1.8
|
L
 -45.7%
H
1.0
2.1
|
L
 -43.8%
H
1.0
8.1
|
L
 -94.2%
H
0.2
29.6
|
L
 -96.9%
H
0.2
39
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
361.8
|
5.2
|
L
 2.6%
H
5.0
5.3
|
L
 5.9%
H
4.9
5.4
|
L
 8.6%
H
4.2
5.4
|
L
 -21.6%
H
4.2
7.3
|
L
 -26.6%
H
4.2
9.6
|
L
 -72.6%
H
4.2
28.9
|
L
 -82.7%
H
4.2
62.1
|
L
H
4.2
62.1
|
| BioNTech SE (ADR) |
|
25,258.1
|
99.9
|
L
 1.5%
H
98.8
100.5
|
L
 11.5%
H
90.1
100.5
|
L
 9.5%
H
84.8
100.5
|
L
 -8.5%
H
79.5
124
|
L
 -2.4%
H
79.5
124
|
L
 -23.0%
H
76.5
131.5
|
L
 -24.7%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
374.0
|
3.4
|
L
 3.1%
H
3.3
3.4
|
L
 9.5%
H
3.0
3.4
|
L
 9.8%
H
2.5
3.4
|
L
 56.3%
H
2.0
3.8
|
L
 189.7%
H
1.1
3.8
|
L
 -57.0%
H
1.0
26.4
|
L
 -70.1%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
10.1
|
0.6
|
L
 3.2%
H
0.6
0.6
|
L
H
0.6
0.7
|
L
 -22.9%
H
0.5
0.9
|
L
 -88.3%
H
0.5
6.0
|
L
 -60.7%
H
0.5
7.2
|
L
 -81.2%
H
0.5
8.6
|
L
 -99.0%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
31.3
|
3.3
|
L
 5.7%
H
3.1
3.3
|
L
 17.2%
H
2.8
3.3
|
L
 -14.8%
H
2.8
4.0
|
L
 -27.9%
H
2.8
4.9
|
L
 -79.9%
H
2.8
43.7
|
L
 -97.8%
H
2.8
168.1
|
L
 -99.7%
H
2.8
1055.5
|
L
 -98.8%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
20.4
|
L
 4.5%
H
19.1
20.4
|
L
 6.1%
H
17.3
20.4
|
L
 82.4%
H
9.9
20.6
|
L
 61.4%
H
8.7
20.6
|
L
 79.7%
H
7.6
21.4
|
L
 547.3%
H
3
21.4
|
L
 67.0%
H
0.9
21.4
|
L
 -66.2%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
278.1
|
2.9
|
L
 3.3%
H
2.8
2.9
|
L
 4.0%
H
2.5
3.0
|
L
 4.8%
H
2.3
3.0
|
L
 22.3%
H
1.7
3.8
|
L
 131.7%
H
1.1
3.8
|
L
 -14.9%
H
1.1
11.9
|
L
 -91.4%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
267.6
|
2.8
|
L
 -1.7%
H
2.7
2.9
|
L
 22.0%
H
2.3
2.9
|
L
 26.3%
H
2.0
2.9
|
L
 42.9%
H
1.6
2.9
|
L
 116.0%
H
1.2
2.9
|
L
 349.2%
H
0.5
3.0
|
L
 -67.3%
H
0.5
9.2
|
L
 -58.6%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
96.5
|
1.1
|
L
 10.2%
H
1.0
1.1
|
L
 31.7%
H
0.8
1.1
|
L
 2.9%
H
0.6
1.2
|
L
 -23.9%
H
0.6
1.5
|
L
 176.9%
H
0.2
3.8
|
L
 -39.3%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
5.1
|
1.4
|
L
 2.9%
H
1.4
1.5
|
L
H
1.4
1.5
|
L
 -49.3%
H
1.4
4.0
|
L
 -39.8%
H
1.4
4.0
|
L
 -87.0%
H
1.4
46.5
|
L
 -97.0%
H
1.4
66.9
|
L
 -99.5%
H
1.4
354.6
|
L
H
1.4
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
77.2
|
12.4
|
L
 -0.3%
H
12.2
12.4
|
L
 18.6%
H
10.2
12.7
|
L
 3.0%
H
9.8
12.7
|
L
 -12.2%
H
9.8
15.9
|
L
 31.9%
H
6.3
21.4
|
L
 -52.7%
H
2.3
43.8
|
L
 24.9%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,896.7
|
36.3
|
L
 -0.4%
H
35.7
36.9
|
L
 2.0%
H
35.7
37.6
|
L
 6.9%
H
32.7
39.4
|
L
 -3.9%
H
32.7
41.4
|
L
 693.2%
H
4.1
43.7
|
L
 253.7%
H
3.7
43.7
|
L
 311.4%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
211.6
|
2.2
|
L
 3.3%
H
2.1
2.2
|
L
 17.7%
H
1.9
2.2
|
L
 16.5%
H
1.7
2.2
|
L
 36.0%
H
1.4
2.2
|
L
 173.8%
H
0.7
3.5
|
L
 -52.2%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
157.5
|
1.4
|
L
 0.7%
H
1.4
1.4
|
L
 0.7%
H
1.3
1.5
|
L
 38.2%
H
0.9
1.5
|
L
 43.9%
H
0.9
1.5
|
L
 36.9%
H
0.9
1.6
|
L
 171.2%
H
0.5
3.1
|
L
 -66.4%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
28.4
|
0.7
|
L
 14.5%
H
0.6
0.7
|
L
 29.1%
H
0.5
0.7
|
L
 -25.3%
H
0.5
1.0
|
L
 -21.1%
H
0.5
1.2
|
L
 -45.0%
H
0.5
3.1
|
L
 -96.2%
H
0.5
20
|
L
 -99.7%
H
0.5
348
|
L
 -99.7%
H
0.5
372
|
| CorMedix Inc |
|
573.1
|
7.3
|
L
 -0.7%
H
7.2
7.4
|
L
 1.1%
H
7.2
7.5
|
L
 12.4%
H
6.2
7.5
|
L
 2.3%
H
6.1
8.5
|
L
 1.7%
H
6.1
17.4
|
L
 37.6%
H
2.6
17.4
|
L
 -8.6%
H
2.6
17.4
|
L
 -63.5%
H
0.9
22.7
|
| CRISPR Therapeutics AG |
|
5,399.2
|
56.3
|
L
 -1.1%
H
55.8
59.4
|
L
 13.2%
H
49.5
59.4
|
L
 15.4%
H
44.1
59.4
|
L
 -1.1%
H
44.1
61.8
|
L
 44.9%
H
33.0
78.5
|
L
 11.8%
H
30.0
91.1
|
L
 -54.3%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
81.5
|
5.9
|
L
 2.4%
H
5.7
5.9
|
L
 -4.4%
H
5.7
6.3
|
L
 -3.8%
H
5.7
6.3
|
L
 -18.3%
H
5.5
7.7
|
L
 -25.7%
H
5.5
9.6
|
L
 22.3%
H
3.6
12.0
|
L
 -49.1%
H
3.6
12.0
|
L
 63.1%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
59.6
|
0.6
|
L
 38.6%
H
0.4
0.7
|
L
 221.1%
H
0.2
0.7
|
L
 117.9%
H
0.2
0.7
|
L
 79.4%
H
0.2
0.7
|
L
 -22.8%
H
0.2
1.0
|
L
 -82.5%
H
0.2
5.1
|
L
 -95.1%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
12.3
|
4.9
|
L
 2.3%
H
4.7
4.9
|
L
 13.4%
H
4.4
5.2
|
L
 -33.8%
H
4.2
7.9
|
L
 -41.7%
H
4.2
9.0
|
L
 -68.3%
H
4.2
17.5
|
L
 260.3%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.9
|
1.7
|
L
 -2.4%
H
1.7
1.8
|
L
 -1.8%
H
1.6
1.8
|
L
 -9.8%
H
1.5
2.2
|
L
 -6.8%
H
1.4
2.2
|
L
 -65.0%
H
1.4
5.9
|
L
 -74.5%
H
1.4
10.2
|
L
 -98.8%
H
1.4
184.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
767.1
|
6.0
|
L
 3.5%
H
5.7
6.0
|
L
 7.4%
H
5.5
6.0
|
L
 -6.9%
H
4.9
6.5
|
L
 -22.0%
H
4.9
8.9
|
L
 97.0%
H
2.3
8.9
|
L
 -40.1%
H
2.3
12.8
|
L
 -83.4%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,363.7
|
21.2
|
L
 5.2%
H
20.2
21.2
|
L
 9.3%
H
19.0
21.2
|
L
 3.1%
H
17.9
23.5
|
L
 16.1%
H
17.2
23.8
|
L
 59.8%
H
12.3
23.8
|
L
 -14.2%
H
10.6
33.3
|
L
 -61.6%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
69.7
|
3.1
|
L
 -0.3%
H
3
3.2
|
L
 10.4%
H
2.8
3.2
|
L
 0.3%
H
2.7
3.4
|
L
 -28.4%
H
2.7
4.4
|
L
 -21.2%
H
2.7
8.4
|
L
 -12.7%
H
0.8
13.6
|
L
 -81.2%
H
0.8
20.6
|
L
 -98.1%
H
0.8
308.4
|
| DarioHealth Corp |
|
53.4
|
7.3
|
L
 -3.2%
H
7.1
7.6
|
L
 14.9%
H
6.2
8.0
|
L
 -18.7%
H
6.2
9.6
|
L
 -38.2%
H
6.2
12.5
|
L
 -45.6%
H
5.9
17.7
|
L
 -90.1%
H
5.9
91.6
|
L
 -98.0%
H
5.9
476
|
L
 -99.6%
H
5.9
2360.0
|
| Bright Minds Biosciences Inc |
|
876.0
|
89.5
|
L
 0.4%
H
87.5
90.3
|
L
 16.4%
H
76.8
90.4
|
L
 24.3%
H
66.2
90.4
|
L
 -0.8%
H
66.2
91
|
L
 173.3%
H
23.2
123.8
|
L
 4265.9%
H
0.9
123.8
|
L
 359.0%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
775.8
|
12.6
|
L
 -0.5%
H
12.4
13.0
|
L
 3.0%
H
11.9
13.0
|
L
 24.3%
H
9.9
13.0
|
L
 28.4%
H
9.0
13.0
|
L
 287.1%
H
3.1
13.0
|
L
 142.4%
H
1.9
13.0
|
L
 -45.7%
H
1.9
29.2
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
192.2
|
7.5
|
L
 3.0%
H
7.0
7.5
|
L
 19.0%
H
5.7
7.5
|
L
 31.4%
H
5.4
7.6
|
L
 80.4%
H
3.5
7.6
|
L
 67.0%
H
3.5
8.8
|
L
 786.9%
H
0.3
19.4
|
L
 -14.5%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,284.0
|
19.9
|
L
 0.5%
H
19.4
21.4
|
L
 9.6%
H
17.9
21.4
|
L
 11.1%
H
16.9
21.4
|
L
 14.0%
H
14
21.4
|
L
 166.4%
H
7.4
25
|
L
 118.7%
H
6.4
47.5
|
L
 16.0%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
326.9
|
3.3
|
L
 -1.5%
H
3.3
3.6
|
L
 21.9%
H
2.7
3.6
|
L
 36.9%
H
2.1
3.6
|
L
 50.5%
H
1.7
3.6
|
L
 153.0%
H
1.2
4.5
|
L
 -56.0%
H
0.9
11.9
|
L
 -92.0%
H
0.9
73.0
|
L
 -91.6%
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
215.2
|
11.7
|
L
 -0.3%
H
11.4
12.2
|
L
 16.0%
H
9.9
12.2
|
L
 -4.1%
H
9.9
12.7
|
L
 45.7%
H
7.4
14.9
|
L
 137.8%
H
4.7
14.9
|
L
 101.7%
H
3.0
24.4
|
L
 -92.3%
H
3.0
162.6
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,620.5
|
43.8
|
L
 -2.3%
H
42.6
44.9
|
L
 1.5%
H
42.4
46.3
|
L
 57.8%
H
26.7
46.3
|
L
 68.2%
H
24.3
46.3
|
L
 154.9%
H
14.8
46.3
|
L
 143.0%
H
9.8
46.3
|
L
 47.6%
H
3.9
46.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
392.7
|
8.2
|
L
 -7.1%
H
8.2
9.2
|
L
 19.7%
H
6.8
9.3
|
L
 16.9%
H
5.9
9.3
|
L
 107.6%
H
3.7
9.3
|
L
 527.5%
H
1.1
9.3
|
L
 161.0%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
196.2
|
0.8
|
L
H
0.8
0.8
|
L
 -1.2%
H
0.7
1.0
|
L
 -21.2%
H
0.7
1.3
|
L
 -15.5%
H
0.7
1.3
|
L
 -7.9%
H
0.7
2.1
|
L
 -71.8%
H
0.7
4.6
|
L
 -92.4%
H
0.7
14.0
|
L
 -99.1%
H
0.7
125.2
|
| Enochian Biosciences Inc |
|
-
|
0.3
|
L
 -10.5%
H
0.3
0.4
|
L
 -12.8%
H
0.3
0.4
|
L
 88.9%
H
0.2
1.0
|
L
 -64.6%
H
0.2
1.1
|
L
 6.3%
H
0.1
1.7
|
L
 -72.1%
H
0.1
2.3
|
L
 -88.8%
H
0.1
13.8
|
L
 -82.6%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
4.8
|
0.5
|
L
H
0.5
0.5
|
L
 -10.3%
H
0.5
0.6
|
L
 26.8%
H
0.4
0.7
|
L
 -44.1%
H
0.3
1.0
|
L
 -73.5%
H
0.3
4.9
|
L
 -87.0%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
131.5
|
2.1
|
L
 8.3%
H
1.9
2.2
|
L
 8.3%
H
1.7
2.2
|
L
 -15.8%
H
1.6
2.7
|
L
 80.9%
H
1.1
2.7
|
L
 324.5%
H
0.3
2.7
|
L
 193.0%
H
0.3
3.3
|
L
 -69.0%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
3,536.7
|
33.0
|
L
 -0.6%
H
32.6
33.3
|
L
 1.5%
H
32.2
34.8
|
L
 11.4%
H
28.9
34.8
|
L
 17.0%
H
25.9
34.8
|
L
 167.4%
H
12.0
34.8
|
L
 467.5%
H
5.1
38.1
|
L
 17.1%
H
5.1
38.1
|
L
H
5.1
40.5
|
| Evaxion Biotech A/S (ADR) |
|
34.5
|
4.1
|
L
H
4.0
4.1
|
L
 9.0%
H
3.8
4.5
|
L
 -2.8%
H
3.3
4.5
|
L
 -18.2%
H
2.9
5.1
|
L
 191.6%
H
1.3
12.2
|
L
 -73.5%
H
0.8
18.5
|
L
 -94.4%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
148.8
|
1.3
|
L
 -4.5%
H
1.3
1.4
|
L
 11.3%
H
1.2
1.5
|
L
 9.4%
H
1.0
1.5
|
L
 18.5%
H
1.0
1.7
|
L
 39.1%
H
0.9
1.9
|
L
 -78.7%
H
0.7
8.8
|
L
 -98.5%
H
0.7
97.4
|
L
 -42.3%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
615.5
|
31.4
|
L
 -3.1%
H
31.4
32.9
|
L
 20.0%
H
25.1
35.8
|
L
 17.5%
H
22.0
35.8
|
L
 -2.1%
H
22.0
35.8
|
L
 461.9%
H
4.9
35.8
|
L
 16.3%
H
4.1
35.8
|
L
 -96.5%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
490.6
|
9.6
|
L
 -0.5%
H
9.4
9.7
|
L
 -6.2%
H
9.4
10.9
|
L
 15.4%
H
8.2
10.9
|
L
 9.7%
H
7.3
10.9
|
L
 245.7%
H
2.8
12.3
|
L
 -40.6%
H
2.2
36.3
|
L
 -74.5%
H
2.2
39.9
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
283.5
|
4.8
|
L
 -0.4%
H
4.8
5.0
|
L
 -2.8%
H
4.5
5.2
|
L
 -1.4%
H
4.4
5.4
|
L
 -23.5%
H
4.4
6.6
|
L
 34.5%
H
3.3
7.0
|
L
 -32.5%
H
2.7
10.2
|
L
 -59.5%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
13.9
|
L
 1.8%
H
13.7
14.5
|
L
 0.1%
H
12.5
14.5
|
L
 8.8%
H
9.9
15.6
|
L
 54.8%
H
8.3
15.6
|
L
 -7.8%
H
5.2
55.9
|
L
 -38.8%
H
5.2
55.9
|
L
 -97.2%
H
5.2
609.5
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
3.2
|
2.1
|
L
 1.5%
H
2.0
2.1
|
L
 -4.6%
H
2
2.3
|
L
 -8.9%
H
1.9
2.6
|
L
 -46.8%
H
1.9
4.1
|
L
 390.5%
H
0.4
5.8
|
L
 -96.1%
H
0.4
73
|
L
 -100.0%
H
0.4
44937.1
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
166.5
|
2.5
|
L
 2.4%
H
2.5
2.6
|
L
 15.5%
H
2.2
2.6
|
L
 -18.1%
H
2.2
3.3
|
L
 -15.7%
H
2.2
3.6
|
L
 88.8%
H
1.2
7.1
|
L
 25.9%
H
0.7
7.1
|
L
 7.2%
H
0.7
7.1
|
L
 67.5%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
90.1
|
2.1
|
L
 12.2%
H
1.9
2.1
|
L
 14.6%
H
1.8
2.1
|
L
 -12.8%
H
1.7
2.7
|
L
 -3.6%
H
1.6
3.1
|
L
 13.4%
H
1.4
4.3
|
L
 -55.7%
H
0.9
6.2
|
L
 -84.9%
H
0.9
15
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
11.2
|
1.0
|
L
 -5%
H
1.0
1
|
L
 -5.9%
H
0.9
1
|
L
 -10.4%
H
0.9
1.1
|
L
 1.1%
H
0.7
1.3
|
L
 -60.9%
H
0.7
3.7
|
L
 -76.3%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
1,089.5
|
1.7
|
L
 -4.0%
H
1.7
1.8
|
L
 -2.3%
H
1.7
1.8
|
L
 7.6%
H
1.4
1.8
|
L
 25.9%
H
1.3
2.0
|
L
 28.8%
H
1.0
2.0
|
L
 -13.7%
H
1.0
5.3
|
L
 12.6%
H
1.0
5.3
|
L
 -48.2%
H
0.8
7.0
|
| Gilead Sciences |
|
172,874.9
|
139.3
|
L
 -0.8%
H
138.1
141.0
|
L
 0.4%
H
137.0
143.0
|
L
 -3.9%
H
133.9
146.7
|
L
 12.3%
H
120.9
157.3
|
L
 30.8%
H
93.4
157.3
|
L
 67.8%
H
62.1
157.3
|
L
 113.3%
H
57.2
157.3
|
L
 41.8%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
356.9
|
25.8
|
L
 -1%
H
25.4
26.7
|
L
 14.4%
H
23.6
28.2
|
L
 -3.7%
H
20.5
30.3
|
L
 -12.1%
H
20
34.1
|
L
 177.6%
H
7.8
34.1
|
L
 118.1%
H
7.6
34.1
|
L
 -27.1%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,454.7
|
18.2
|
L
 3.9%
H
17.4
18.2
|
L
 6.2%
H
16.9
18.5
|
L
 13.5%
H
14.2
18.5
|
L
 -24.4%
H
14.2
25.4
|
L
 312.2%
H
3.5
25.8
|
L
 165.4%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
2.9
|
1.3
|
L
 -3.7%
H
1.3
1.3
|
L
 6.6%
H
1.1
1.4
|
L
 -25%
H
1.1
1.8
|
L
 -54.9%
H
1.1
3.4
|
L
 -95.2%
H
1.1
34.8
|
L
 -99.5%
H
1.1
288.4
|
L
 -99.9%
H
1.1
2812.5
|
L
 -100.0%
H
1.1
379518072.3
|
| Graphite Bio Inc |
|
576.5
|
9.9
|
L
 2.8%
H
9.7
10.2
|
L
 2.0%
H
9.0
10.3
|
L
 -18.5%
H
8.3
12.7
|
L
 -46.8%
H
8.3
21.8
|
L
 -63.1%
H
8.3
50.4
|
L
 -91.9%
H
8.3
413
|
L
H
8.3
1666
|
L
H
8.3
1666
|
| Galapagos NV (ADR) |
|
1,915.6
|
29.1
|
L
 0.7%
H
28.8
29.3
|
L
 0.5%
H
28.0
29.4
|
L
 -8.3%
H
28.0
33.4
|
L
 -14.8%
H
28.0
36.2
|
L
 20.1%
H
23.4
37.8
|
L
 -24.2%
H
22.4
45.2
|
L
 -63.9%
H
22.4
83.8
|
L
 -33.4%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
8,007.7
|
67.6
|
L
 0.4%
H
67.1
67.9
|
L
 6.3%
H
64.1
68.3
|
L
 6.2%
H
61.3
68.3
|
L
 -7.4%
H
61.3
82.2
|
L
 10.1%
H
47.5
82.2
|
L
 89.6%
H
29.9
82.2
|
L
 47.1%
H
29.9
82.2
|
L
 471.8%
H
7.7
82.2
|
| HCW Biologics Inc |
|
2.6
|
0.4
|
L
 11.4%
H
0.4
0.4
|
L
 44.4%
H
0.3
0.4
|
L
 -25%
H
0.3
1.2
|
L
 -66.1%
H
0.3
1.7
|
L
 -95.3%
H
0.3
17.8
|
L
 -99.4%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
39.8
|
3.4
|
L
 2.4%
H
3.4
3.6
|
L
 8.3%
H
3.0
3.6
|
L
 -16.7%
H
3.0
4.4
|
L
 10.8%
H
2.7
5.8
|
L
 154.9%
H
1.1
9.1
|
L
 -87.4%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
181.0
|
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 21.5%
H
0.8
1.0
|
L
 9.1%
H
0.7
1.0
|
L
 -35.6%
H
0.7
1.5
|
L
 -50.3%
H
0.7
2.6
|
L
 -64.8%
H
0.5
3.9
|
L
 -94.4%
H
0.5
19.0
|
L
 -95.3%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
18.2
|
3.1
|
L
 3.3%
H
3.0
3.3
|
L
 -19.6%
H
2.8
4.1
|
L
 25.8%
H
2.2
6.5
|
L
 -55.5%
H
2.1
7.3
|
L
 -53.6%
H
2.1
38.3
|
L
 -97.4%
H
2.1
123.3
|
L
 -97.3%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
159.9
|
0.7
|
L
 4.4%
H
0.7
0.7
|
L
 18.0%
H
0.6
0.7
|
L
 -37.9%
H
0.6
1.2
|
L
 -36.8%
H
0.6
1.3
|
L
 -51.7%
H
0.6
2.9
|
L
 -77.8%
H
0.6
10.0
|
L
 -93.5%
H
0.6
17.5
|
L
H
0.6
17.5
|
| Immucell Corp |
|
68.1
|
7.5
|
L
 -2.6%
H
7.5
7.8
|
L
 14.1%
H
6.4
7.8
|
L
 18.2%
H
6
7.8
|
L
 13.8%
H
5.8
7.8
|
L
 36.9%
H
4.5
7.8
|
L
 53.4%
H
3.3
7.8
|
L
 -18.7%
H
3.3
11.1
|
L
 13.9%
H
3.3
13.2
|
| InflaRx N.V. |
|
86.8
|
1.2
|
L
 5.3%
H
1.1
1.3
|
L
 23.7%
H
0.9
1.3
|
L
 26.3%
H
0.8
1.3
|
L
 12.2%
H
0.8
1.3
|
L
 22.5%
H
0.7
1.9
|
L
 -72.3%
H
0.7
5.2
|
L
 -68.3%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
64.0
|
5.7
|
L
 -0.2%
H
5.5
6.2
|
L
 20.4%
H
4.5
6.6
|
L
 -3.2%
H
3.9
6.6
|
L
 -16.3%
H
3.9
7.6
|
L
 -59.3%
H
3.9
18
|
L
 -90.5%
H
3.9
91.7
|
L
 -97.3%
H
3.9
317.9
|
L
H
3.9
451.3
|
| Illumina Inc |
|
20,129.2
|
132.5
|
L
 1.7%
H
130.2
133.4
|
L
 4.8%
H
118.3
133.4
|
L
 11.4%
H
116.7
133.4
|
L
 -8.0%
H
112.7
155.5
|
L
 76.5%
H
69.9
155.5
|
L
 -41.9%
H
68.7
232.2
|
L
 -66.7%
H
68.7
526
|
L
 -23.2%
H
68.7
555.8
|
| Immunome Inc |
|
2,603.2
|
23.0
|
L
 0.5%
H
22.5
23.3
|
L
 6.6%
H
21.4
23.7
|
L
 13.0%
H
19.2
23.7
|
L
 10.8%
H
19.2
27.7
|
L
 213.1%
H
7.0
27.7
|
L
 377.4%
H
4.4
31.0
|
L
 -17.3%
H
2.1
32.5
|
L
H
2.1
63.8
|
| Imunon Inc |
|
12.0
|
3.1
|
L
 -1.3%
H
3.0
3.2
|
L
 -1.9%
H
2.9
3.2
|
L
 2.3%
H
2.5
3.2
|
L
 -16.2%
H
2.5
3.9
|
L
 -76.6%
H
2.5
47.4
|
L
 -81.8%
H
2.5
54.8
|
L
 -98.9%
H
2.5
348.8
|
L
 -99.9%
H
2.5
5607
|
| Immatics N.V |
|
1,469.7
|
11.0
|
L
 0.1%
H
10.8
11.1
|
L
 6.9%
H
10.2
11.1
|
L
 18.6%
H
9.1
11.1
|
L
 11.5%
H
8.6
11.1
|
L
 159.1%
H
3.9
12.4
|
L
 75.9%
H
3.3
13.8
|
L
 -9.2%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
5,536.1
|
27.2
|
L
 2.5%
H
26.5
27.3
|
L
 10.5%
H
24.4
27.3
|
L
 11.4%
H
22.8
27.3
|
L
 -0.6%
H
22.8
29.3
|
L
 76.3%
H
13.4
29.3
|
L
 90.6%
H
12.7
45.6
|
L
 70.9%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
13.4
|
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -4.9%
H
1.3
1.5
|
L
 -28.0%
H
1.3
2.1
|
L
 -38.5%
H
1.3
2.7
|
L
 750%
H
0.1
4.2
|
L
 12.4%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,903.5
|
82.4
|
L
 -1.0%
H
79.8
85.9
|
L
 32.1%
H
65.4
85.9
|
L
 19.9%
H
57.3
85.9
|
L
 8.5%
H
57.3
88.7
|
L
 593.5%
H
10.8
94.6
|
L
 351.5%
H
10.8
94.6
|
L
 295.7%
H
7.7
94.6
|
L
H
7.7
94.6
|
| MiNK Therapeutics Inc |
|
64.0
|
12.9
|
L
 -4.6%
H
12.5
13.8
|
L
 11.1%
H
10.9
13.8
|
L
 32.3%
H
8.5
13.8
|
L
 10.0%
H
8.5
16.9
|
L
 70.5%
H
6.3
76
|
L
 -41.7%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
34.0
|
1.3
|
L
 1.6%
H
1.3
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 -2.3%
H
1.1
1.4
|
L
 -16.9%
H
1.1
1.8
|
L
 -83.1%
H
1.1
11.6
|
L
 -85.2%
H
1.1
14.7
|
L
 -89.1%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
1,520.1
|
3.7
|
L
 1.4%
H
3.5
3.7
|
L
 11.1%
H
3.3
4.3
|
L
 -6.8%
H
3.2
4.3
|
L
 55.0%
H
2.2
5.6
|
L
 8.2%
H
1.6
5.6
|
L
 -34.6%
H
1.6
18.3
|
L
 -87.7%
H
1.6
33.6
|
L
 -35.9%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
467.3
|
2.6
|
L
 9.7%
H
2.4
2.6
|
L
 15.0%
H
2.2
2.6
|
L
 11.1%
H
1.9
2.7
|
L
 28.7%
H
1.7
3.0
|
L
 420%
H
0.4
3.0
|
L
 -16.4%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,681.1
|
70.3
|
L
 -0.3%
H
69.7
71.0
|
L
 5.1%
H
65.5
71.0
|
L
 17.0%
H
57.7
71.0
|
L
 -8.9%
H
40
83.9
|
L
 74.5%
H
39.2
99.5
|
L
 220.1%
H
21.7
99.5
|
L
 -39.1%
H
11.6
129.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
477.9
|
1.7
|
L
 5.0%
H
1.6
1.7
|
L
 31.0%
H
1.3
1.8
|
L
 -2.9%
H
1.2
1.9
|
L
 -35%
H
1.2
2.6
|
L
 225%
H
0.5
3.1
|
L
 44.4%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,585.7
|
31.3
|
L
 -1.3%
H
31.1
32.2
|
L
 -2.1%
H
30.8
32.8
|
L
 1.4%
H
28.9
32.8
|
L
 -5.6%
H
28.9
36.0
|
L
 16.2%
H
26.4
40.7
|
L
 -42.9%
H
23.2
77.0
|
L
 -20.8%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
86.9
|
0.6
|
L
 84.4%
H
0.6
1.1
|
L
 63.9%
H
0.3
1.1
|
L
 22.9%
H
0.3
1.1
|
L
 -81.0%
H
0.3
3.2
|
L
 -60.4%
H
0.3
3.5
|
L
 -62.9%
H
0.3
3.9
|
L
 -83.0%
H
0.3
5.4
|
L
 -80.8%
H
0.3
8.0
|
| Inventiva (ADR) |
|
1,183.6
|
5.7
|
L
 3.5%
H
5.4
5.8
|
L
 6.7%
H
4.9
5.8
|
L
 -4.8%
H
4.9
6.3
|
L
 -4.7%
H
4.9
7.3
|
L
 73.3%
H
2.9
8.0
|
L
 87.5%
H
1.5
8.0
|
L
 -58.1%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
901.5
|
14.8
|
L
 -2.8%
H
14.6
15.1
|
L
 -0.7%
H
14.4
15.5
|
L
 9.1%
H
13.0
15.5
|
L
 5.0%
H
12.1
15.5
|
L
 -48.8%
H
12.1
35.3
|
L
 1.2%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
28.8
|
1.0
|
L
 10.8%
H
0.9
1.0
|
L
 53.7%
H
0.7
1.0
|
L
 -15.6%
H
0.6
1.3
|
L
 -36.4%
H
0.6
1.7
|
L
 -75.5%
H
0.6
7.2
|
L
 -29.0%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
484.0
|
8.4
|
L
 -0.4%
H
8.4
8.5
|
L
 1.7%
H
8.3
8.6
|
L
 -3.6%
H
8.0
9.1
|
L
 5.4%
H
7.7
9.4
|
L
 33.6%
H
6.2
9.4
|
L
 82.8%
H
4.1
9.4
|
L
 35.8%
H
3.7
9.4
|
L
 112.9%
H
3.6
13.3
|
| Kodiak Sciences Inc |
|
2,616.2
|
42.3
|
L
 -6.2%
H
42.2
45.5
|
L
 1.2%
H
40.5
46.7
|
L
 82.4%
H
21
46.7
|
L
 47.5%
H
20.9
46.7
|
L
 1840.4%
H
2.2
46.7
|
L
 746%
H
1.4
46.7
|
L
 -63.4%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
7,874.1
|
267.5
|
L
 -0.9%
H
262.4
271.1
|
L
 1.3%
H
252.3
275.8
|
L
 8.2%
H
242
275.8
|
L
 -8.3%
H
242
298.3
|
L
 58.4%
H
122.8
298.3
|
L
 209.7%
H
82.1
298.3
|
L
 257.8%
H
38.9
298.3
|
L
H
8.0
298.3
|
| TuHURA Biosciences Inc |
|
198.4
|
3.1
|
L
 -1.0%
H
3.0
3.4
|
L
 110.8%
H
1.6
3.4
|
L
 64.2%
H
1.3
3.4
|
L
 310.5%
H
0.4
3.4
|
L
 -25.7%
H
0.4
4.4
|
L
 -96.9%
H
0.2
209.3
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
799.8
|
9.0
|
L
 -1.4%
H
8.9
9.3
|
L
 2.2%
H
8.6
9.3
|
L
 4.2%
H
7.5
9.3
|
L
 -3.7%
H
7.4
9.6
|
L
 54.0%
H
5.5
12.5
|
L
 -21.2%
H
5.4
24.2
|
L
 -69.1%
H
5.4
30.4
|
L
 158.2%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
7,244.9
|
88.7
|
L
 -1.3%
H
87.7
90.1
|
L
 4.3%
H
84.2
90.1
|
L
 12.3%
H
73.3
90.1
|
L
 18.0%
H
66.2
95.9
|
L
 249.0%
H
24.4
103
|
L
 170.1%
H
9.6
103
|
L
 144.5%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
54.3
|
7.4
|
L
H
7.3
7.4
|
L
 -0.4%
H
7.3
7.5
|
L
 7.5%
H
6.1
7.6
|
L
 19.3%
H
6.0
7.6
|
L
 70.4%
H
3.5
7.6
|
L
 -69.1%
H
0.7
31.3
|
L
 -88.1%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Longeveron Inc (Class A) |
|
31.9
|
1.1
|
L
 -2.7%
H
1.1
1.1
|
L
 -6.0%
H
1.1
1.2
|
L
 12.4%
H
0.8
1.2
|
L
 94.6%
H
0.5
1.2
|
L
 -24.3%
H
0.5
1.8
|
L
 -96.1%
H
0.5
44
|
L
 -98.5%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
36.0
|
3.1
|
L
 6.5%
H
3.0
3.1
|
L
 8.8%
H
2.7
3.1
|
L
 -0.3%
H
2.5
3.2
|
L
 -13.4%
H
2.4
4.0
|
L
 160.5%
H
0.6
6.3
|
L
 -50.8%
H
0.6
9.5
|
L
 -89.6%
H
0.6
49.5
|
L
 -63.1%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
81.0
|
0.9
|
L
 -5.3%
H
0.9
1.0
|
L
 23.3%
H
0.8
1.1
|
L
 55.2%
H
0.6
1.1
|
L
 -21.1%
H
0.5
1.2
|
L
 164.7%
H
0.2
3.7
|
L
 -77.1%
H
0.2
10.2
|
L
 -94.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
501.8
|
4.8
|
L
 -0.8%
H
4.8
5
|
L
 -4.2%
H
4.7
5.4
|
L
 5%
H
4.2
5.4
|
L
 41.6%
H
2.7
6.4
|
L
 158.3%
H
1.7
6.4
|
L
 6.6%
H
1.6
13.7
|
L
 -62.4%
H
1.5
15.5
|
L
 -94.3%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
554.5
|
23.8
|
L
 1.7%
H
23.0
24.3
|
L
 9.1%
H
21.4
25.3
|
L
 11.9%
H
17.3
25.3
|
L
 1.3%
H
17.3
27.9
|
L
 167.1%
H
7.7
45
|
L
 -49.6%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
157.8
|
2.4
|
L
 -3.3%
H
2.3
2.5
|
L
 2.6%
H
2.2
2.7
|
L
 -12.6%
H
2.2
2.8
|
L
 8.8%
H
1.6
2.9
|
L
 3.1%
H
1.6
4.7
|
L
 32.0%
H
0.8
4.7
|
L
 -70.3%
H
0.8
9.6
|
L
 -99.4%
H
0.8
598.4
|
| Seres Therapeutics Inc |
|
83.8
|
8.7
|
L
 1.5%
H
8.5
8.9
|
L
 -1.2%
H
8.3
9.2
|
L
 1.3%
H
8.1
9.6
|
L
 -45.7%
H
7.9
16.3
|
L
 1224.2%
H
0.4
30.0
|
L
 49.1%
H
0.4
30.0
|
L
 -57.7%
H
0.4
30.0
|
L
 -70.8%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
913.0
|
11.2
|
L
 -0.7%
H
11.1
11.9
|
L
 17.9%
H
8.9
11.9
|
L
 51.7%
H
7.0
11.9
|
L
 50.5%
H
6.6
11.9
|
L
 104.6%
H
4.6
11.9
|
L
 111.1%
H
3.5
11.9
|
L
 -18.2%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,481.8
|
30.1
|
L
 10.2%
H
27
31.1
|
L
 6.3%
H
26.1
31.1
|
L
 14.9%
H
22.4
31.1
|
L
 -9.9%
H
22.4
34.7
|
L
 116.2%
H
12.6
47.7
|
L
 128.0%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
381.1
|
56.9
|
L
 -1.7%
H
56.6
59.7
|
L
 6.2%
H
54.7
60.1
|
L
 -5.7%
H
50.5
64.9
|
L
 -18.2%
H
50.5
76.1
|
L
 51.9%
H
28.4
105
|
L
 802.4%
H
1.4
105
|
L
 114.1%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
26.0
|
1.6
|
L
 -1.9%
H
1.5
1.6
|
L
 12.2%
H
1.4
1.8
|
L
 17.3%
H
1.2
1.8
|
L
 -14.3%
H
1.2
2.3
|
L
 41.8%
H
0.8
4.1
|
L
 41.8%
H
0.8
9.7
|
L
 -92.6%
H
0.7
36.5
|
L
 -97.9%
H
0.7
135.5
|
| Moderna |
|
21,582.3
|
54.4
|
L
 3.0%
H
53.3
55.2
|
L
 8.6%
H
50.0
55.2
|
L
 3.5%
H
47.1
56.5
|
L
 34.1%
H
36.7
59.6
|
L
 103.1%
H
22.3
59.6
|
L
 -65.4%
H
22.3
170.5
|
L
 -66.0%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
494.8
|
3.4
|
L
 3.1%
H
3.3
3.4
|
L
 17.0%
H
3
3.4
|
L
 9.7%
H
2.8
3.4
|
L
 -14.2%
H
2.8
4.0
|
L
 91.0%
H
1.7
4.1
|
L
 -76.0%
H
1.7
16.6
|
L
 -90.9%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
90.8
|
0.9
|
L
 -3.4%
H
0.8
0.9
|
L
 19.7%
H
0.7
0.9
|
L
 3.7%
H
0.7
0.9
|
L
 -33.6%
H
0.6
1.4
|
L
 -67.3%
H
0.6
3.0
|
L
 -84.1%
H
0.6
5.5
|
L
 -85.5%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
6.9
|
0.6
|
L
 -9.8%
H
0.5
0.6
|
L
 14.6%
H
0.4
0.6
|
L
 -25.7%
H
0.4
0.7
|
L
 -50.9%
H
0.4
1.6
|
L
 -83.7%
H
0.4
4.4
|
L
 -99.8%
H
0.4
242.4
|
L
H
0.4
1200
|
L
H
0.4
1200
|
| Mesoblast Ltd (ADR) |
|
2,025.5
|
15.7
|
L
 7.6%
H
15.5
15.9
|
L
 14.9%
H
13.8
15.9
|
L
 8.0%
H
13.3
16.5
|
L
 -10.9%
H
13.3
19.3
|
L
 46.4%
H
9.9
21.5
|
L
 357.0%
H
1.0
22
|
L
 80.7%
H
1.0
22
|
L
 67.9%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
157.1
|
4.2
|
L
 1.5%
H
4.2
4.2
|
L
 8.5%
H
4
4.5
|
L
 -0.5%
H
3.7
5.0
|
L
 -0.2%
H
3.7
5.4
|
L
 8.8%
H
3.4
5.4
|
L
 -35.7%
H
3.3
12.7
|
L
 -82.8%
H
3.3
32.0
|
L
 -84.3%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
51.1
|
0.3
|
L
 -3.0%
H
0.3
0.4
|
L
 -3.0%
H
0.3
0.4
|
L
 -18.0%
H
0.3
0.4
|
L
 -55.6%
H
0.3
0.7
|
L
 -83.2%
H
0.2
3.1
|
L
 -69.5%
H
0.2
5.0
|
L
 -90.8%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
401.2
|
3.2
|
L
 3.6%
H
3.0
3.2
|
L
 1.6%
H
2.8
3.4
|
L
 36.1%
H
2.3
4.3
|
L
 65.1%
H
1.8
4.3
|
L
 306.4%
H
0.6
4.3
|
L
 12.0%
H
0.6
4.7
|
L
 -73.8%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
164.7
|
2.3
|
L
 0.9%
H
2.3
2.3
|
L
 2.7%
H
2.1
2.4
|
L
 2.2%
H
2.0
2.4
|
L
 11.6%
H
1.9
2.8
|
L
 35.9%
H
1.6
2.8
|
L
 -48.9%
H
1.3
16.2
|
L
 -93.6%
H
1.3
40.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
20.8
|
L
 7.7%
H
19.3
21.3
|
L
 -0.7%
H
19.1
22.1
|
L
 -3.5%
H
18.2
23.4
|
L
 10.4%
H
15.9
26.4
|
L
 15.4%
H
14.7
37.3
|
L
 31.4%
H
12.2
37.3
|
L
 -91.5%
H
7.5
268
|
L
 -89.4%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.7
|
L
 0.9%
H
7.7
7.8
|
L
 3.9%
H
7.5
7.8
|
L
 -1.9%
H
7.0
8.0
|
L
 -5.2%
H
7.0
8.8
|
L
 8.4%
H
6.2
8.8
|
L
 476.1%
H
0.0
8.8
|
L
 -67.0%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
7.4
|
1.5
|
L
 -2.7%
H
1.4
1.5
|
L
 19.8%
H
1.2
1.6
|
L
 -9.9%
H
1.2
1.6
|
L
 -73.3%
H
1.2
4.3
|
L
 -92.8%
H
1.2
23.1
|
L
 -97.7%
H
1.2
83.6
|
L
 -100.0%
H
1.2
17344.8
|
L
H
1.2
1424940
|
| Intellia Therapeutics Inc |
|
1,734.2
|
14.7
|
L
 -0.7%
H
14.5
15.3
|
L
 8.3%
H
13.3
15.3
|
L
 15.1%
H
11.6
15.3
|
L
 22.1%
H
10.9
17.1
|
L
 95.7%
H
6.7
28.3
|
L
 -61.5%
H
5.9
47.5
|
L
 -80.8%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,213.9
|
104.5
|
L
 -0.5%
H
103.8
106.7
|
L
 2.2%
H
99.8
107.1
|
L
 6.7%
H
93.9
107.1
|
L
 -3.1%
H
93.9
113.0
|
L
 49.3%
H
63.6
113.0
|
L
 268.7%
H
28.7
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,430.6
|
8.8
|
L
 4.7%
H
8.4
8.8
|
L
 10.0%
H
8.0
8.8
|
L
 -14.3%
H
7.6
10.9
|
L
 7.2%
H
7.6
12.0
|
L
 37.0%
H
5.8
12.0
|
L
 -4.1%
H
3.5
23.9
|
L
 -95.6%
H
3.5
277.8
|
L
 -92.1%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
9.0
|
2.2
|
L
 0.5%
H
2.2
2.2
|
L
 5.9%
H
1.8
2.3
|
L
 13.6%
H
1.3
2.3
|
L
 -34.8%
H
1.3
3.5
|
L
 -100.0%
H
1.3
50000
|
L
 -100.0%
H
1.3
960000
|
L
 -100.0%
H
1.3
4620000
|
L
H
1.3
32000000
|
| Insight Molecular Diagnostics Inc |
|
110.0
|
3.4
|
L
 -5.3%
H
3.2
3.9
|
L
 6.5%
H
2.6
4.1
|
L
 -30.4%
H
2.4
5.0
|
L
 -50.1%
H
2.4
7.5
|
L
 20.4%
H
2.3
8.5
|
L
 -46.4%
H
1.9
8.5
|
L
 -96.6%
H
1.9
125
|
L
 -96.8%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
88.2
|
1.7
|
L
 6.3%
H
1.6
1.7
|
L
 5%
H
1.5
1.7
|
L
 1.2%
H
1.4
1.7
|
L
 -40.6%
H
1.4
2.9
|
L
 55.6%
H
1.1
3.4
|
L
 40%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
124.3
|
1.1
|
L
 4.9%
H
1.0
1.1
|
L
 18.9%
H
0.9
1.1
|
L
 9.2%
H
0.8
1.1
|
L
 1.9%
H
0.8
1.3
|
L
 81.4%
H
0.3
1.5
|
L
 -7.0%
H
0.3
3.4
|
L
 -65.1%
H
0.3
3.4
|
L
 -71.8%
H
0.3
8.5
|
| Traws Pharma Inc |
|
9.3
|
1.2
|
L
 -27.0%
H
1.1
1.4
|
L
 -27.5%
H
1.1
1.7
|
L
 -42%
H
1.1
2.3
|
L
 -34.5%
H
1.1
3.0
|
L
 -45.3%
H
1.0
3.3
|
L
 -93.1%
H
1.0
36.3
|
L
 -99.6%
H
1.0
412.5
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.3
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -7.4%
H
1.4
1.7
|
L
 -16.7%
H
1.3
1.9
|
L
 -25.4%
H
1.3
3.4
|
L
 -10.2%
H
1.3
5.3
|
L
 -94.1%
H
0.3
26.9
|
L
 -98.6%
H
0.3
135
|
L
 -99.8%
H
0.3
1197.6
|
| Passage Bio Inc |
|
38.1
|
11.9
|
L
 9.5%
H
9.8
11.9
|
L
 44.7%
H
8.0
11.9
|
L
 59.6%
H
5.9
11.9
|
L
 -21.6%
H
5.9
16.1
|
L
 55.2%
H
5.1
20
|
L
 -44.4%
H
5.1
35.8
|
L
 -96.4%
H
5.1
396.8
|
L
H
5.1
764.6
|
| Vaxcyte Inc |
|
8,754.7
|
60.8
|
L
 -3.1%
H
60.4
62.8
|
L
 0.2%
H
59.0
63.3
|
L
 11.5%
H
52.7
63.3
|
L
 25.4%
H
44.9
65
|
L
 89.9%
H
28.1
65
|
L
 66.7%
H
27.7
121.1
|
L
 205.7%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
116.8
|
1.7
|
L
H
1.7
1.8
|
L
 1.2%
H
1.6
1.8
|
L
 -68.2%
H
1.3
5.5
|
L
 -67.2%
H
1.3
7.1
|
L
 53.6%
H
1.0
7.8
|
L
 -81.8%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,387.4
|
3.9
|
L
 -1.5%
H
3.9
4.0
|
L
 -4.9%
H
3.9
4.4
|
L
 11.7%
H
3.0
4.4
|
L
 -11.1%
H
3.0
5.5
|
L
 180%
H
1.2
5.5
|
L
 273.3%
H
0.7
5.5
|
L
 -46.1%
H
0.7
8.7
|
L
 -89.7%
H
0.7
38.6
|
| Phio Pharma Corp |
|
14.9
|
1.3
|
L
 -0.8%
H
1.3
1.3
|
L
 3.2%
H
1.2
1.3
|
L
 9.4%
H
1.1
1.4
|
L
 14.3%
H
0.8
1.9
|
L
 -41.8%
H
0.8
4.2
|
L
 -97.2%
H
0.6
110.4
|
L
 -99.5%
H
0.6
307.8
|
L
 -100.0%
H
0.6
194238
|
| Pliant Therapeutics Inc |
|
81.7
|
1.3
|
L
 1.5%
H
1.3
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 -2.2%
H
1.1
1.4
|
L
 0.8%
H
1.1
1.4
|
L
 -7.0%
H
1.1
2.0
|
L
 -95.0%
H
1.1
30.9
|
L
 -95.6%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
34.0
|
3.4
|
L
 -0.6%
H
3.4
3.5
|
L
 -0.6%
H
3.2
3.5
|
L
 -0.3%
H
3.0
3.5
|
L
 10.1%
H
3
3.9
|
L
 -13.3%
H
2.8
7.1
|
L
 -53.6%
H
0.7
8.6
|
L
 -90.4%
H
0.7
40.5
|
L
 -97.6%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
313.8
|
5.0
|
L
 13.2%
H
4.3
5.2
|
L
 13.2%
H
3.8
5.2
|
L
 50.9%
H
2.8
5.2
|
L
 120.4%
H
1.8
5.2
|
L
 621.7%
H
0.7
5.2
|
L
 -38.7%
H
0.6
8.6
|
L
 -86.6%
H
0.6
45.3
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
673.5
|
3.7
|
L
 0.8%
H
3.7
3.8
|
L
 9.4%
H
3.3
3.9
|
L
 2.2%
H
3.0
3.9
|
L
 -13.5%
H
3.0
4.8
|
L
 180.5%
H
1.1
6.9
|
L
 -72.1%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
281.0
|
2.0
|
L
 3.7%
H
1.9
2.0
|
L
 8.2%
H
1.8
2.0
|
L
 -12%
H
1.6
2.3
|
L
 -13.2%
H
1.6
2.6
|
L
 167.6%
H
0.5
7.1
|
L
 -83.9%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
579.8
|
10.8
|
L
 1.5%
H
10.5
10.9
|
L
 4.0%
H
10.2
10.9
|
L
 16.9%
H
8.4
10.9
|
L
 17.1%
H
8.2
10.9
|
L
 8.4%
H
4.3
11.7
|
L
 -78.6%
H
4.3
79.7
|
L
 -55.1%
H
4.3
79.8
|
L
 -77.2%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
7.7
|
0.3
|
L
H
0.3
0.3
|
L
 6.5%
H
0.3
0.4
|
L
 -13.2%
H
0.3
0.4
|
L
 -64.1%
H
0.3
1.0
|
L
 -96.3%
H
0.3
15.8
|
L
 -99.5%
H
0.3
88
|
L
 -99.9%
H
0.3
899.5
|
L
 -99.8%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
6,608.0
|
103.6
|
L
 -1.1%
H
103.0
106.7
|
L
 -0.2%
H
95.4
106.7
|
L
 12.1%
H
90.6
107.8
|
L
 21.5%
H
77
107.8
|
L
 130.0%
H
41.3
107.8
|
L
 452.6%
H
13.7
107.8
|
L
 298.5%
H
6.9
107.8
|
L
H
4.5
107.8
|
| PureTech Health Plc ADR |
|
445.9
|
18.3
|
L
 2.5%
H
17.2
18.4
|
L
 17.9%
H
15.7
18.4
|
L
 10.1%
H
14.5
18.4
|
L
 -3.4%
H
14.5
19.9
|
L
 9.8%
H
14.5
19.9
|
L
 -33.4%
H
13.3
34
|
L
 -68.3%
H
13.3
59.9
|
L
H
13.3
65.9
|
| Quince Therapeutics Inc |
|
18.9
|
1.2
|
L
 -7.2%
H
1.1
1.2
|
L
 -28.8%
H
1.1
3.8
|
L
 8.4%
H
0.8
3.8
|
L
 -96.2%
H
0.8
37.2
|
L
 -88.6%
H
0.8
45.5
|
L
 -92.5%
H
0.8
45.5
|
L
 -99.7%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,073.0
|
17.2
|
L
 0.4%
H
16.8
17.6
|
L
 0.1%
H
13.2
18.2
|
L
 10.5%
H
13.2
18.2
|
L
 -23.2%
H
8.7
28.5
|
L
 87.1%
H
8.7
71.5
|
L
 -12.2%
H
3.7
71.5
|
L
 -50.8%
H
3.7
71.5
|
L
 31.8%
H
3.7
82.5
|
| Rain Oncology Inc |
|
82.2
|
2.3
|
L
 1.4%
H
2.2
2.3
|
L
 -17.8%
H
2.0
2.9
|
L
 -22.9%
H
2.0
3.8
|
L
 -35.4%
H
2.0
3.8
|
L
 -5.0%
H
2.0
9.2
|
L
 -69.7%
H
0.8
10.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
95.7
|
1.0
|
L
 14.3%
H
0.8
1.0
|
L
 17.1%
H
0.7
1.0
|
L
 -27.3%
H
0.7
1.4
|
L
 -31.4%
H
0.7
1.4
|
L
 -22.0%
H
0.4
3.9
|
L
 -81.7%
H
0.4
8.8
|
L
 -99.5%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
419.0
|
3.8
|
L
 5.5%
H
3.7
3.9
|
L
 10.3%
H
3.5
3.9
|
L
 -18.8%
H
3.3
5.1
|
L
 -3.0%
H
3
5.5
|
L
 -35.0%
H
2.2
8.3
|
L
 -78.5%
H
2.2
32.5
|
L
 -91.2%
H
2.2
49.7
|
L
 -89.6%
H
2.2
67.5
|
| Replimune Grp Inc |
|
179.2
|
2.2
|
L
 11.3%
H
1.9
2.3
|
L
 -72.2%
H
1.5
8.2
|
L
 -69.6%
H
1.5
8.9
|
L
 -71.9%
H
1.5
9.1
|
L
 -71.1%
H
1.5
13.2
|
L
 -86.5%
H
1.5
24.8
|
L
 -92.9%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.7
|
1.3
|
L
 4.2%
H
1.2
1.3
|
L
 10.6%
H
1.1
1.3
|
L
 -0.8%
H
1.1
1.3
|
L
 -65.3%
H
1.1
5.8
|
L
 -97.0%
H
1.1
43.5
|
L
 -100.0%
H
1.1
9561.6
|
L
 -100.0%
H
1.1
2276064
|
L
H
1.1
2276064
|
| Relay Therapeutics Inc |
|
2,729.1
|
15.3
|
L
 3.5%
H
14.3
15.3
|
L
 13.3%
H
13.8
15.9
|
L
 47.4%
H
9.3
15.9
|
L
 89.2%
H
7.0
15.9
|
L
 494.2%
H
2.5
15.9
|
L
 -12.4%
H
1.8
18.3
|
L
 -55.2%
H
1.8
38.6
|
L
H
1.8
64.4
|
| TransCode Therapeutics Inc |
|
7.8
|
8.6
|
L
 -3.9%
H
8.6
8.9
|
L
 -1.7%
H
7.9
10.3
|
L
 -12.6%
H
7.9
10.3
|
L
 -5.2%
H
7.9
12.6
|
L
 -25.5%
H
6.1
22.0
|
L
 -100.0%
H
6.1
328648.8
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,949.1
|
3.7
|
L
 4.2%
H
3.6
3.7
|
L
 15.7%
H
3.2
3.7
|
L
 7.9%
H
2.8
3.7
|
L
 -23.9%
H
2.8
5.2
|
L
 -33.0%
H
2.8
7.2
|
L
 -37.9%
H
2.8
16.7
|
L
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
5,958.6
|
87.3
|
L
 0.0%
H
85.9
90
|
L
 0.7%
H
83.0
90.1
|
L
 -0.1%
H
74.5
100
|
L
 -23.0%
H
74.5
114
|
L
 45.1%
H
55.3
122.2
|
L
 349.8%
H
15.5
122.2
|
L
 320.5%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
279.7
|
4.0
|
L
 3.1%
H
3.8
4.0
|
L
 5.9%
H
3.7
4.0
|
L
 -4.1%
H
3.7
4.3
|
L
 -0.5%
H
3.5
5.2
|
L
 186.3%
H
1.3
6.6
|
L
 445.2%
H
0.4
6.6
|
L
 -60.2%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
918.0
|
3.4
|
L
 -1.2%
H
3.3
3.7
|
L
 9.2%
H
3.1
4.1
|
L
 2.4%
H
2.7
4.1
|
L
 -27.4%
H
2.7
5.2
|
L
 90.1%
H
1.5
6.6
|
L
 -33.7%
H
1.3
12
|
L
 -86.3%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
77.3
|
1.6
|
L
 0.6%
H
1.5
1.6
|
L
 -4.2%
H
1.5
1.8
|
L
 -19.6%
H
1.5
2.0
|
L
 -25.6%
H
1.5
2.5
|
L
 19.4%
H
1.3
5.0
|
L
 -93.1%
H
1.2
42.2
|
L
 -95.5%
H
1.2
146.2
|
L
 -90.0%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
110.0
|
2.0
|
L
 0.5%
H
1.9
2.0
|
L
 15.4%
H
1.7
2.0
|
L
 7.7%
H
1.7
2.0
|
L
 1.6%
H
1.7
2.2
|
L
 -6.7%
H
1.7
2.4
|
L
 -50%
H
1.5
5.7
|
L
 -96.4%
H
1.5
55.0
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
983.3
|
6.4
|
L
 7.1%
H
5.9
6.4
|
L
 1.1%
H
5.8
6.6
|
L
 -14.1%
H
5.6
8.0
|
L
 -16.9%
H
5.6
9.3
|
L
 -38.1%
H
5.6
15.6
|
L
 -38.1%
H
5.6
15.6
|
L
 -38.1%
H
5.6
15.6
|
L
 -38.1%
H
5.6
15.6
|
| Sangamo Therapeutics Inc |
|
111.9
|
0.3
|
L
 3.9%
H
0.3
0.3
|
L
 3.9%
H
0.3
0.3
|
L
 -29.0%
H
0.2
0.4
|
L
 -37.2%
H
0.2
0.6
|
L
 -64%
H
0.2
0.8
|
L
 -83.6%
H
0.2
3.2
|
L
 -97.7%
H
0.2
12.8
|
L
 -96.2%
H
0.2
27.5
|
| Solid Biosciences Inc |
|
808.8
|
8.2
|
L
 -0.1%
H
8
8.4
|
L
 6.2%
H
7.6
8.9
|
L
 12.5%
H
6.4
8.9
|
L
 41.5%
H
5.2
8.9
|
L
 203.3%
H
2.4
8.9
|
L
 62.1%
H
1.8
15.1
|
L
 -89.7%
H
1.8
81.9
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
16,352.6
|
21.1
|
L
 1.2%
H
21.1
22.2
|
L
 9.7%
H
18.8
22.2
|
L
 30.8%
H
15.3
22.2
|
L
 19.5%
H
13.8
22.2
|
L
 -19.3%
H
13.8
36.9
|
L
 1243.3%
H
1.3
36.9
|
L
 279.3%
H
0.7
36.9
|
L
 201.3%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
2,132.7
|
24.2
|
L
 -1.0%
H
23.9
24.7
|
L
 -1.9%
H
23.9
25.4
|
L
 2.9%
H
22.4
25.6
|
L
 12.8%
H
19.2
25.6
|
L
 115.1%
H
8.6
25.6
|
L
 20.9%
H
8.6
25.6
|
L
 11.5%
H
8.6
29.9
|
L
 54.8%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
35.5
|
26.5
|
L
 -7.7%
H
25.8
29.3
|
L
 -12.2%
H
25.8
32.3
|
L
 -17.9%
H
23.0
36.1
|
L
 121.2%
H
8.4
36.8
|
L
 245.1%
H
5.3
36.8
|
L
 -11.7%
H
5
38.8
|
L
 -91.0%
H
5
302.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
29.0
|
0.9
|
L
H
0.9
1.0
|
L
 8.1%
H
0.8
1.0
|
L
H
0.8
1
|
L
 -15.5%
H
0.8
1.2
|
L
 -71.7%
H
0.8
5.1
|
L
 -91.3%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
93.3
|
68.0
|
L
 0.3%
H
66.8
71.5
|
L
 9.4%
H
59.3
71.5
|
L
 13.2%
H
55.9
80
|
L
 -13.3%
H
48.1
87.4
|
L
 188.6%
H
4.3
240
|
L
 -53.3%
H
4.3
446.3
|
L
 -94.3%
H
4.3
1349.3
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
153.4
|
2.7
|
L
 -4.7%
H
2.6
2.8
|
L
 -0.8%
H
2.6
2.9
|
L
 2.7%
H
2.2
2.9
|
L
 5.6%
H
2.1
2.9
|
L
 278.6%
H
0.6
3.2
|
L
 54.1%
H
0.5
3.2
|
L
 -79.9%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
5,659.1
|
49.3
|
L
 -0.6%
H
49.0
50.0
|
L
 -1.3%
H
48.5
51.6
|
L
 23.1%
H
38.8
51.6
|
L
 8.1%
H
38.8
51.6
|
L
 70.3%
H
27.1
51.6
|
L
 515.0%
H
5.6
51.6
|
L
 64.0%
H
4.3
51.6
|
L
H
4.3
70
|
| Surrozen Inc |
|
367.6
|
31.3
|
L
 -1.9%
H
30.6
33.2
|
L
 21.3%
H
25.1
33.2
|
L
 24.0%
H
23.6
33.2
|
L
 56.3%
H
18.0
33.2
|
L
 229.3%
H
5.9
33.2
|
L
 4495.6%
H
0.3
33.2
|
L
H
0.3
33.2
|
L
H
0.3
33.2
|
| Stoke Therapeutics Inc |
|
2,088.6
|
35.3
|
L
 -1.5%
H
35.0
36.3
|
L
 4.5%
H
34.0
36.8
|
L
 6.4%
H
29.9
36.8
|
L
 14.0%
H
27.0
40.2
|
L
 367.1%
H
7.3
40.2
|
L
 332.2%
H
3.4
40.2
|
L
 2.9%
H
3.4
41.6
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
531.3
|
7.0
|
L
 3.7%
H
6.7
7.3
|
L
 3.7%
H
6.4
7.7
|
L
 17.4%
H
5.8
7.7
|
L
 48.6%
H
3.5
7.7
|
L
 698.9%
H
0.7
7.7
|
L
 145.8%
H
0.7
11.8
|
L
 -78.8%
H
0.7
38.9
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
5.0
|
1.9
|
L
 -14.0%
H
1.9
2.4
|
L
 7.9%
H
1.7
2.4
|
L
 -20.1%
H
1.3
2.6
|
L
H
1.3
8.6
|
L
 -85.4%
H
1.3
17.7
|
L
H
1.3
2076
|
L
H
1.3
2076
|
L
H
1.3
2076
|
| Alaunos Therapeutics Inc |
|
7.2
|
3.0
|
L
 0.7%
H
2.9
3.0
|
L
 3.1%
H
2.8
3.1
|
L
 -8.8%
H
2.7
3.5
|
L
 9.9%
H
2.3
3.7
|
L
 19.9%
H
1.7
6.2
|
L
 428.1%
H
0.0
6.2
|
L
 -12.8%
H
0.0
6.2
|
L
 -65.1%
H
0.0
9.2
|
| Tscan Therapeutics Inc |
|
59.7
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 -1.9%
H
1
1.2
|
L
H
0.9
1.2
|
L
 -12.5%
H
0.9
1.3
|
L
 -15.3%
H
0.9
2.6
|
L
 -52.1%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
9,188.5
|
58.7
|
L
 0.1%
H
58.5
59.8
|
L
 9.1%
H
53.4
60.4
|
L
 15.5%
H
48.3
60.4
|
L
 -14.1%
H
48.3
72.2
|
L
 11.8%
H
46.0
72.2
|
L
 -31.1%
H
46.0
89.9
|
L
 -43.3%
H
46.0
136.0
|
L
 155.8%
H
22.9
136.0
|
| Terns Pharma Inc |
|
6,085.7
|
52.7
|
L
 0.1%
H
52.7
52.8
|
L
 0.2%
H
52.6
52.8
|
L
 13.4%
H
45.1
53.2
|
L
 41.8%
H
33.5
53.2
|
L
 2182.7%
H
2.2
53.2
|
L
 358.1%
H
1.9
53.2
|
L
 143.6%
H
1.5
53.2
|
L
H
1.5
53.2
|
| Instil Bio Inc |
|
60.2
|
8.9
|
L
 5.1%
H
8.4
9
|
L
 5.0%
H
7.9
9
|
L
 7.4%
H
7.5
9
|
L
 23.4%
H
6.8
9.8
|
L
 -47.2%
H
5.7
42.8
|
L
 1264.6%
H
0.3
92
|
L
 -55.7%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
3,513.0
|
24.6
|
L
 2.3%
H
23.8
25.1
|
L
 24.3%
H
19.6
25.1
|
L
 42.3%
H
17.3
25.1
|
L
 98.7%
H
10.8
25.1
|
L
 1737.3%
H
1.0
25.1
|
L
 477.9%
H
1.0
25.1
|
L
H
1.0
25.1
|
L
H
1.0
25.1
|
| Entrada Therapeutics Inc |
|
530.2
|
13.9
|
L
 -1.3%
H
13.7
14.2
|
L
H
13.3
14.5
|
L
 9.1%
H
11.0
14.5
|
L
 30.9%
H
9.8
14.5
|
L
 74.9%
H
4.9
14.5
|
L
 -19.7%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
1,813.0
|
14.1
|
L
 0.6%
H
13.8
14.2
|
L
 7.8%
H
12.7
14.2
|
L
 28.3%
H
10.3
14.2
|
L
 23.4%
H
9.8
14.2
|
L
 137.3%
H
5.4
14.4
|
L
 647.1%
H
1.0
14.4
|
L
 464.8%
H
0.5
14.4
|
L
H
0.5
14.4
|
| Taysha Gene Therapies Inc |
|
1,689.1
|
5.9
|
L
 24.8%
H
4.7
6.0
|
L
 28.7%
H
4.3
6.0
|
L
 31.0%
H
4.0
6.0
|
L
 16.7%
H
4.0
6.0
|
L
 359.4%
H
1.1
6.0
|
L
 575.9%
H
0.5
6.0
|
L
 -77.0%
H
0.5
27.0
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
3,485.0
|
56.8
|
L
 -1.0%
H
56.3
59.9
|
L
 13.4%
H
47.1
59.9
|
L
 31.3%
H
41.5
59.9
|
L
 42.0%
H
39.1
59.9
|
L
 42.7%
H
23.3
59.9
|
L
 306.9%
H
11.5
60.9
|
L
 -60.0%
H
11.5
149.2
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
3,236.0
|
25.3
|
L
 2.1%
H
24.6
25.7
|
L
 16.1%
H
22.2
25.7
|
L
 34.8%
H
15.9
25.7
|
L
 21.1%
H
15.9
25.7
|
L
 205.9%
H
7.3
25.7
|
L
 -53.1%
H
6.8
63.6
|
L
 -86.8%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
1,037.9
|
21.3
|
L
 0.5%
H
20.7
21.5
|
L
 18.3%
H
18.3
22.0
|
L
 15.6%
H
16.5
22.0
|
L
 13.8%
H
16.5
22.5
|
L
 101.1%
H
3.4
30
|
L
 121.4%
H
3.4
30
|
L
 20.9%
H
3.4
30
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
3,083.7
|
43
|
L
 -3.1%
H
42.5
44.6
|
L
 7.5%
H
39.6
47
|
L
 7.6%
H
37.5
47
|
L
 -11.2%
H
37.5
49.5
|
L
 100%
H
18.8
56.1
|
L
 585.8%
H
6.1
56.1
|
L
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,610.9
|
10.1
|
L
 0.3%
H
10.0
10.3
|
L
 9.9%
H
9.1
10.3
|
L
 8.9%
H
8.3
10.3
|
L
 47.8%
H
5.8
10.9
|
L
 81.0%
H
4.2
10.9
|
L
 -58.9%
H
4.2
27.5
|
L
 -77.9%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
765.9
|
15.7
|
L
 -1.2%
H
15.4
16.2
|
L
 -6.9%
H
15.2
17.3
|
L
 16.1%
H
11.7
19.7
|
L
 6.2%
H
11.5
19.7
|
L
 2172.5%
H
0.1
50.0
|
L
 232.2%
H
0.1
50.0
|
L
 -53.5%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
552.5
|
6.3
|
L
 2.4%
H
6.2
6.6
|
L
 15.4%
H
5.2
6.6
|
L
 12.3%
H
4.8
6.6
|
L
 -7.4%
H
4.8
7.1
|
L
 31.6%
H
4.0
11.2
|
L
 33.8%
H
2.1
15.2
|
L
 -80.4%
H
2.1
59.2
|
L
 -65.3%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
23.8
|
0.6
|
L
H
0.6
0.6
|
L
 11.1%
H
0.5
0.6
|
L
 -1.6%
H
0.5
0.7
|
L
 -14.3%
H
0.4
0.7
|
L
 -73.1%
H
0.4
5.1
|
L
 -85.6%
H
0.4
24.7
|
L
 -99.0%
H
0.4
106.5
|
L
 -99.8%
H
0.4
262.5
|
| Voyager Therapeutics Inc |
|
242.0
|
4.1
|
L
 3.1%
H
4.0
4.1
|
L
 2.5%
H
3.7
4.1
|
L
 -9.0%
H
3.7
4.6
|
L
 -1.7%
H
3.3
5.5
|
L
 27.3%
H
2.6
5.6
|
L
 -49.7%
H
2.6
14.3
|
L
 -15.2%
H
2.5
14.3
|
L
 -67.3%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
530.8
|
6.1
|
L
 0.3%
H
6
6.3
|
L
 2.7%
H
5.9
6.4
|
L
 -42.4%
H
5.8
11.5
|
L
 -41.1%
H
5.8
12.2
|
L
 -13.3%
H
5.4
12.3
|
L
 -46.1%
H
3.6
17.1
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
1,421.3
|
7.6
|
L
 2.2%
H
7.3
7.7
|
L
 6.3%
H
7.0
7.7
|
L
 -42.0%
H
5.0
13.4
|
L
 -48.0%
H
5.0
15.5
|
L
 25.8%
H
5.0
21.7
|
L
 68.2%
H
3.2
21.7
|
L
 20.6%
H
1.2
21.7
|
L
 -40.4%
H
1.2
56
|
| XBiotech Inc |
|
75.3
|
2.5
|
L
 1.7%
H
2.5
2.5
|
L
 7.9%
H
2.3
2.5
|
L
 6.9%
H
2.2
2.5
|
L
 -5.4%
H
2.2
2.7
|
L
 -20.8%
H
2.1
3.6
|
L
 -30.6%
H
2.1
10.0
|
L
 -85.4%
H
2.1
18.5
|
L
 -79.5%
H
2.1
26.4
|
| Exicure Inc |
|
24.6
|
3.9
|
L
 1.9%
H
3.8
3.9
|
L
 0.5%
H
3.8
4.2
|
L
 -8.1%
H
3.7
5.1
|
L
 -35.7%
H
3.5
6.6
|
L
 -67.1%
H
3.1
12.7
|
L
 -24.3%
H
0.3
36
|
L
 -98.6%
H
0.3
304.4
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,055.3
|
6.1
|
L
 0.8%
H
6.1
6.1
|
L
 4.3%
H
5.8
6.2
|
L
 12.1%
H
5.3
6.2
|
L
 -19.3%
H
5.3
7.9
|
L
 47.1%
H
4.0
10.1
|
L
 182.0%
H
1.5
10.1
|
L
 50.4%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
389.1
|
4.3
|
L
 1.9%
H
4.2
4.3
|
L
 14.8%
H
3.8
4.3
|
L
 16.0%
H
3.5
4.5
|
L
 13.5%
H
2.8
4.8
|
L
 2040%
H
0.2
6.6
|
L
 272.2%
H
0.2
6.6
|
L
 -52.2%
H
0.2
9.9
|
L
H
0.2
172.2
|
| Xencor Inc |
|
905.0
|
12.3
|
L
 -1.4%
H
12.3
12.8
|
L
 0.2%
H
12.0
13.3
|
L
 2.8%
H
11.0
13.3
|
L
 -14.6%
H
10.6
14.7
|
L
 38.0%
H
6.9
18.7
|
L
 -57.8%
H
6.9
30.2
|
L
 -71.4%
H
6.9
45.4
|
L
 -16.2%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.5
|
2.1
|
L
 4.4%
H
2.0
2.1
|
L
 -0.9%
H
1.8
2.3
|
L
 -44.9%
H
1.7
4.0
|
L
 -83.4%
H
1.7
13.3
|
L
 -99.3%
H
1.7
489.9
|
L
 -100.0%
H
1.7
8423696.6
|
L
 -100.0%
H
1.7
67850460
|
L
 -100.0%
H
1.7
67850460
|
| Zentalis Pharma Inc |
|
366.0
|
5.2
|
L
 -0.8%
H
4.9
5.3
|
L
 93.3%
H
2.7
7.0
|
L
 90.4%
H
2.1
7.0
|
L
 47.0%
H
2.1
7.0
|
L
 323.0%
H
1.1
7.0
|
L
 -71.7%
H
1.0
31.5
|
L
 -89.0%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
537.0
|
5.7
|
L
 -1.1%
H
5.6
5.9
|
L
 0.2%
H
5.5
6
|
L
 -8.3%
H
5.2
6.6
|
L
 5.4%
H
4.4
7.4
|
L
 405.4%
H
1.0
7.4
|
L
 -48.5%
H
1.0
14
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,603.8
|
23.1
|
L
 5.2%
H
22.4
23.2
|
L
 10.1%
H
20.4
23.2
|
L
 25.8%
H
17.3
23.2
|
L
 17.9%
H
16.0
23.2
|
L
 -26.7%
H
16.0
44.3
|
L
 -40.0%
H
13.5
44.3
|
L
 -86.0%
H
13.5
181.9
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
6,613.8
|
88.7
|
L
 0.2%
H
86.1
89.2
|
L
 6.5%
H
81.5
89.6
|
L
 23.3%
H
65.2
89.6
|
L
 7.6%
H
60.4
89.6
|
L
 166.4%
H
31.4
89.6
|
L
H
14.2
89.6
|
L
H
14.2
89.6
|
L
H
14.2
89.6
|
| Intensity Therapeutics Inc |
|
13.5
|
5.3
|
L
 -1.1%
H
5.2
5.4
|
L
 1.0%
H
5.1
5.8
|
L
 -21.8%
H
5.1
6.8
|
L
 -50.1%
H
5.1
11.1
|
L
 -88.7%
H
4.6
50
|
L
 -94.7%
H
4.6
286
|
L
 -94.7%
H
4.6
286
|
L
 -94.7%
H
4.6
286
|
| Renovaro Biosciences Inc |
|
10.2
|
0.3
|
L
 -17.7%
H
0.3
0.4
|
L
 -28.2%
H
0.3
0.4
|
L
 55.6%
H
0.2
1.0
|
L
 -70.8%
H
0.2
1.1
|
L
 -92.2%
H
0.2
5.5
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
| Elutia Inc (Class A) |
|
50.1
|
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 8.3%
H
1.0
1.2
|
L
 39.3%
H
0.7
1.4
|
L
 -41.8%
H
0.5
2.6
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Canton Strategic Holdings Inc |
|
205.7
|
3.6
|
L
 7.1%
H
3.4
3.6
|
L
 16.0%
H
3.0
3.6
|
L
 -10.8%
H
3.0
4.4
|
L
 18.6%
H
2.7
5.8
|
L
 207.6%
H
1.1
9.1
|
L
 -99.1%
H
0.3
472.5
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
728.7
|
8.0
|
L
 1.8%
H
7.9
8.0
|
L
 12.1%
H
7.0
8.0
|
L
 5.6%
H
6.6
8.0
|
L
 3.8%
H
6.6
9.1
|
L
 3.4%
H
6.6
11.8
|
L
 6.4%
H
5.6
130.5
|
L
 6.4%
H
5.6
130.5
|
L
 6.4%
H
5.6
130.5
|
| Lexeo Therapeutics Inc |
|
491.2
|
6.6
|
L
 -0.6%
H
6.4
6.8
|
L
 5.1%
H
5.9
6.9
|
L
 -0.5%
H
5.0
6.9
|
L
 -14.1%
H
5.0
8
|
L
 209.8%
H
2.1
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
195.4
|
13.6
|
L
 -2.7%
H
13.3
14.1
|
L
 -2.6%
H
12.5
14.5
|
L
 5.9%
H
9.9
15.6
|
L
 50.6%
H
8.3
15.6
|
L
 5.5%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
158.3
|
6.0
|
L
 -6.0%
H
6.0
6.5
|
L
 -4.9%
H
5.8
6.6
|
L
 -19.2%
H
5.6
8.0
|
L
 -21.9%
H
5.6
9.3
|
L
 -54.1%
H
5.6
15.6
|
L
 -99.5%
H
5.6
1278
|
L
 -99.8%
H
5.6
4752
|
L
H
5.6
25199.6
|
| Elevai Labs Inc |
|
7.5
|
3.9
|
L
 -11.9%
H
3.6
4.1
|
L
 11.9%
H
3.6
7
|
L
 -15.7%
H
1.6
14
|
L
 -81.9%
H
1.6
30.6
|
L
 -98.6%
H
1.6
309.1
|
L
H
1.6
499117.9
|
L
H
1.6
499117.9
|
L
H
1.6
499117.9
|
| Spyre Therapeutics Inc |
|
5,269.1
|
66.9
|
L
 4.5%
H
64.6
68.3
|
L
 30.6%
H
50.4
75
|
L
 67.7%
H
40.7
75
|
L
 101.7%
H
30.9
75
|
L
 413.7%
H
12.0
75
|
L
H
8.8
75
|
L
H
8.8
75
|
L
H
8.8
75
|
| Neurogene Inc |
|
372.7
|
23.9
|
L
 15.3%
H
20.9
24.1
|
L
 14.4%
H
19.1
24.1
|
L
 11.3%
H
18.2
24.1
|
L
 27.3%
H
15.9
26.4
|
L
 119.7%
H
10.5
37.3
|
L
 68.8%
H
6.9
74.5
|
L
 68.8%
H
6.9
74.5
|
L
 68.8%
H
6.9
74.5
|
| Cg Oncology Inc |
|
5,673.2
|
67.2
|
L
 -0.1%
H
65.9
68.2
|
L
 -3.8%
H
65.9
71.9
|
L
 4.5%
H
62.8
71.9
|
L
 21.0%
H
48.5
71.9
|
L
 235.0%
H
19.5
71.9
|
L
H
14.8
71.9
|
L
H
14.8
71.9
|
L
H
14.8
71.9
|
| FibroBiologics Inc |
|
6.1
|
1.4
|
L
 -4.3%
H
1.3
1.4
|
L
 -4.9%
H
1.3
1.6
|
L
 -78.4%
H
1.0
6.5
|
L
 -80.2%
H
1.0
9.6
|
L
 -93.1%
H
1.0
30.6
|
L
H
1.0
1100
|
L
H
1.0
1100
|
L
H
1.0
1100
|
| Kyverna Therapeutics Inc |
|
564.1
|
9.3
|
L
 -0.4%
H
9.2
9.6
|
L
 -0.1%
H
8.9
9.8
|
L
 4.1%
H
7.3
9.8
|
L
 1.8%
H
7.2
10.6
|
L
 317.9%
H
1.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
53.4
|
1.4
|
L
 -0.7%
H
1.4
1.5
|
L
 4.4%
H
1.4
1.5
|
L
 -2.7%
H
1.3
1.5
|
L
 -17.9%
H
1.3
1.8
|
L
 -6.6%
H
1.3
4.0
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
26.4
|
6.3
|
L
 6.0%
H
6.0
6.6
|
L
 27.3%
H
5.1
6.6
|
L
 17.8%
H
4.1
6.6
|
L
 -60.1%
H
4.1
18.5
|
L
 -87.9%
H
4.1
75.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
| NeOnc Tech Holdings Inc |
|
126.2
|
5.1
|
L
 -4.8%
H
5.0
5.7
|
L
 -11.9%
H
4.5
6.2
|
L
 -40.7%
H
4.5
9.7
|
L
 -45.1%
H
4.5
11.4
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
299.4
|
9.6
|
L
 -3.5%
H
9.5
10.2
|
L
 -1.7%
H
9.0
10.3
|
L
 -21.4%
H
8.3
12.7
|
L
 -48.6%
H
8.3
21.8
|
L
 -58.9%
H
8.3
50.4
|
L
 -61.7%
H
8.3
50.4
|
L
 -61.7%
H
8.3
50.4
|
L
 -61.7%
H
8.3
50.4
|
| Boundless Bio Inc |
|
37.2
|
1.7
|
L
 6.4%
H
1.6
1.7
|
L
 45.6%
H
1.1
1.7
|
L
 49.6%
H
1.1
1.7
|
L
 31.8%
H
1.0
1.7
|
L
 33.9%
H
1.0
1.8
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
487.6
|
13.1
|
L
 0.7%
H
12.9
13.5
|
L
 2.6%
H
12.4
13.5
|
L
 0.5%
H
11.8
14.2
|
L
 11.1%
H
10.8
16.3
|
L
 227.3%
H
3.4
16.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
455.7
|
7.4
|
L
 2.6%
H
7.2
7.6
|
L
 9.5%
H
6.5
7.6
|
L
 0.7%
H
6.5
8.0
|
L
 -12.1%
H
6.5
9.3
|
L
 139.0%
H
3.0
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
7.6
|
2.3
|
L
 10.2%
H
2.1
2.3
|
L
 5.1%
H
2
2.3
|
L
 0.4%
H
1.9
2.6
|
L
 -41.3%
H
1.9
4.1
|
L
 86.1%
H
1.0
5.8
|
L
 -72.8%
H
0.6
9.5
|
L
 -72.8%
H
0.6
9.5
|
L
 -72.8%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
218.5
|
8.8
|
L
 18.0%
H
7.7
9.2
|
L
 32.5%
H
6.1
9.2
|
L
 43.0%
H
4.7
9.2
|
L
 84.9%
H
3.6
9.2
|
L
 351.0%
H
1.5
9.2
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,549.8
|
32.6
|
L
 -0.6%
H
31.8
33.2
|
L
 8.1%
H
30.4
33.8
|
L
 16.5%
H
26.1
33.8
|
L
 -24.1%
H
26.1
44.9
|
L
 339.0%
H
6.9
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
| BioAge Labs Inc |
|
747.8
|
16.9
|
L
 1.7%
H
16.3
17.1
|
L
 -4.3%
H
15.8
18.7
|
L
 -10.0%
H
15.5
22
|
L
 -26.5%
H
15.5
24
|
L
 350.5%
H
3.6
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
61.7
|
4.5
|
L
 -2.0%
H
4.4
4.7
|
L
 5.1%
H
4.0
4.7
|
L
 19.3%
H
3.6
4.8
|
L
 41.4%
H
2.2
4.8
|
L
 48.4%
H
1.7
4.8
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.7
|
L
 3.5%
H
4.5
5.0
|
L
 0.7%
H
4.4
5.1
|
L
 -13.5%
H
3.9
5.9
|
L
 -21.0%
H
3.3
7.8
|
L
 103.5%
H
1.3
7.8
|
L
 103.5%
H
1.3
7.8
|
L
 103.5%
H
1.3
7.8
|
L
 103.5%
H
1.3
7.8
|
| Upstream Bio Inc |
|
538.8
|
9.9
|
L
 -4.3%
H
9.9
10.5
|
L
 2.1%
H
9.5
10.7
|
L
 7.3%
H
8.1
10.7
|
L
 -69.4%
H
7.3
32.8
|
L
 30.6%
H
7.3
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
11.8
|
0.3
|
L
 -25%
H
0.3
0.5
|
L
 -33.3%
H
0.3
0.5
|
L
 -45.5%
H
0.3
0.5
|
L
 -79.3%
H
0.3
1.7
|
L
 -95.5%
H
0.3
8.9
|
L
 -95.5%
H
0.3
8.9
|
L
 -95.5%
H
0.3
8.9
|
L
 -95.5%
H
0.3
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,597.8
|
10.6
|
L
 -0.8%
H
10.4
10.7
|
L
 10.3%
H
9.7
11.5
|
L
 35.3%
H
7.8
11.5
|
L
 39.4%
H
6.3
11.5
|
L
 -36.9%
H
6.3
19.9
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
1,840.7
|
128.6
|
L
 -0.7%
H
125.6
133.3
|
L
 7.1%
H
118.5
134.0
|
L
 5.4%
H
108.6
134.4
|
L
 22.1%
H
72.2
151.2
|
L
 426.2%
H
20.2
151.2
|
L
 845.6%
H
11.2
151.2
|
L
 845.6%
H
11.2
151.2
|
L
 845.6%
H
11.2
151.2
|
| Sionna Therapeutics Inc |
|
2,030.3
|
45.1
|
L
 4.2%
H
42.6
45.2
|
L
 22.7%
H
36.2
45.2
|
L
 20.9%
H
33.2
45.2
|
L
 9.6%
H
32.5
45.2
|
L
 406.4%
H
8.6
45.2
|
L
H
7.3
45.2
|
L
H
7.3
45.2
|
L
H
7.3
45.2
|
| Zenas Biopharma Inc |
|
1,300.9
|
20.9
|
L
 -2.3%
H
20.5
21.7
|
L
 -7.2%
H
20.1
23
|
L
 -13.2%
H
17.2
24.1
|
L
 -7.5%
H
17.2
29.6
|
L
 99.2%
H
8.9
44.6
|
L
 99.2%
H
8.9
44.6
|
L
 99.2%
H
8.9
44.6
|
L
 99.2%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
2.4
|
0.1
|
L
 10%
H
0.1
0.2
|
L
 -8.3%
H
0.1
0.2
|
L
 -15.4%
H
0.1
0.2
|
L
 -73.8%
H
0.1
0.4
|
L
 -96.2%
H
0.1
9.4
|
L
 -96.2%
H
0.1
9.4
|
L
 -96.2%
H
0.1
9.4
|
L
 -96.2%
H
0.1
9.4
|
| SpyGlass Pharma Inc |
|
834.3
|
25.0
|
L
 1.8%
H
24.1
25.1
|
L
 18.5%
H
20.4
25.3
|
L
 -6.0%
H
20.2
28.2
|
L
 -5.5%
H
20.2
30.6
|
L
 -5.5%
H
20.2
30.6
|
L
 -5.5%
H
20.2
30.6
|
L
 -5.5%
H
20.2
30.6
|
L
 -5.5%
H
20.2
30.6
|
| AgomAb Therapeutics NV ADR |
|
525.7
|
10.7
|
L
 2.0%
H
10.2
11.0
|
L
 1.6%
H
9
11.2
|
L
 -22.9%
H
9
14.6
|
L
 -27.1%
H
9
17.5
|
L
 -27.1%
H
9
17.5
|
L
 -27.1%
H
9
17.5
|
L
 -27.1%
H
9
17.5
|
L
 -27.1%
H
9
17.5
|
| Generate Biomedicines Inc |
|
1,586.8
|
12.5
|
L
 -3.4%
H
12.4
13.1
|
L
 5.2%
H
11.1
13.4
|
L
 -4.8%
H
11.1
14.2
|
L
 -1.6%
H
11
14.2
|
L
 -1.6%
H
11
14.2
|
L
 -1.6%
H
11
14.2
|
L
 -1.6%
H
11
14.2
|
L
 -1.6%
H
11
14.2
|
| AnaptysBio Inc When Issued |
|
-
|
45.5
|
L
H
45.5
46.9
|
L
 4.7%
H
42.0
49.8
|
L
 0.0%
H
42.0
49.8
|
L
 0.0%
H
42.0
49.8
|
L
 0.0%
H
42.0
49.8
|
L
 0.0%
H
42.0
49.8
|
L
 0.0%
H
42.0
49.8
|
L
 0.0%
H
42.0
49.8
|